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Sarvesh Chelvanambi 
MECHANISMS OF HIV-NEF INDUCED ENDOTHELIAL CELL STRESS: 
IMPLICATIONS OF HIV-NEF PROTEIN PERSISTENCE IN AVIREMIC HIV 
PATIENTS  
 
HIV-associated cardio-pulmonary vascular pathologies such as coronary artery 
disease, pulmonary hypertension and emphysema remain a major issue in the HIV-
infected population even in the era of antiretroviral therapy (ART). The continued 
production of HIV encoded pro-apoptotic protein, such as Nef in latently HIV-infected 
cells is a possible mechanism for vascular dysfunction underlying these diseases. HIV-
Nef persists in two compartments in these patients: (i) extracellular vesicles (EV) of 
plasma and bronchoalveolar lavage (BAL) fluid and (ii) PBMC and BAL derived cells. 
Here I demonstrate that the presence of HIV-Nef protein in cells and EV is capable of 
stressing endothelial cells by inducing ROS production leading to endothelial cell 
apoptosis. HIV-Nef protein hijacks host cell signaling by interacting with small GTP 
binding protein Rac1 which activates PAK2 to promote the release of pro-apoptotic cargo 
containing EV and surface expression of pro-apoptotic protein Endothelial Monocyte 
Activating Polypeptide II (EMAPII).  Using this mechanism, Nef protein robustly 
induces apoptosis in Human Coronary Artery Endothelial Cells and Human Lung 
microvascular endothelial cells. Endothelial specific expression of HIV-Nef protein in 
transgenic mice was sufficient to induce vascular pathologies as evidenced by impaired 
endothelium mediated vasodilation of the aorta and vascular remodeling and emphysema 
like alveolar rarefaction in the lung. Furthermore, EV isolated from HIV patients on ART 
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was capable of inducing endothelial apoptosis in a Nef dependent fashion. Of therapeutic 
interest, EMAPII neutralizing antibodies to block EMAPII mediated apoptosis and statin 
treatment to ameliorate Nef induced Rac1 signaling was capable of blocking Nef induced 
endothelial stress in both in vivo and in vitro. In conclusion, HIV-Nef protein uses a 
Rac1-Pak2 signaling axis to promote its dissemination in EV, which in turn induces 
endothelial cell stress after its uptake. 
 
Matthias Clauss, PhD., Chair 
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I Introduction 
1 Vascular disease in HIV patients 
1.1 HIV in the era of combined and highly effective anti-retroviral therapy 
Before combined and highly effective anti-retroviral therapy (ART) was 
developed in the 1990s infection with HIV in most cases would lead to acquired immune 
deficiency syndrome (AIDS). Back in the 1980s, HIV infection comprised a near death 
sentence with only few exceptions such as elite controllers – individuals who could 
mount an immune response against the virus without the aid of ART. The discovery of 
combined ART transformed this illness to a completely treatable condition by the late 
1990s/ early 2000s. However, it soon became obvious that although ART could protect 
against development of AIDS, it failed to prevent the increased risk for developing so-
called comorbidities, such as cardiovascular, pulmonary and renal diseases as well as 
disturbing pathologies within the central nervous system which were classified under 
HIV-associated neurocognitive disorders (HAND). This work will focus on pulmonary 
ad cardiovascular complications in association with treated HIV infection  
1.2 Vascular disease in HIV patients 
Although anti-retroviral therapy regimens resulted into good control of viral 
replication, this patient population continues to remain at higher risk for developing a 
wide variety of cardio-pulmonary vascular diseases than the general population. Initially, 
ART itself was a contributor to this heightened risk in HIV positive patients. But despite 
the switch to regimens with low metabolic syndrome effects and vascular toxicity, this 
elevated risk of developing cardiovascular pathologies continues to persist in this 
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population. In the following, I have collected examples of studies addressing these 
cardiovascular complications starting out with studies using untreated (viremic) patients:    
HIV infection itself serves to increase the risk of developing cardiovascular 
diseases (CVD) which continues to persist despite the initiation of antiretroviral therapy. 
A study of 255 HIV infected adults cataloged carotid intima-media thickness (CIMT) and 
coronary calcium (CAC) scores at baseline and 3 yr after initiation of antiretroviral 
therapy and observed higher CIMT and CAC progression rates in HIV-infected patients 
[1]. These findings are supported by the lack of normalization of other risk markers like 
triglycerides, LDL cholesterol, hemoglobin, or FIB-4 in another study of 297 HIV 
infected veterans after bringing viral loads below detectable levels [2]. Similarly, a meta-
analysis comprising of five studies and 89,713 subjects provided further support of 
cardiovascular disease risk persistence in the era of ART. While RNA viral load [log of 
odds ratio = 1.10 (1.04-1.17)] and CD4+ cell count less than 200/μl were related to stroke, 
ART therapy did not normalize the increased risk of stroke [3].  
HIV infection itself acts as an independent predictor for developing 
cardiovascular diseases. Priscilla Hsue and colleagues established HIV infection as an 
independent predictor of increased Carotid Intima-Media Thickness (CIMT) when 
looking at blood lipids, inflammatory markers and IMT in 148 HIV-infected adults [4].  
Furthermore, HIV infection was associated with a younger age at the time of first cardiac 
intervention when compared to uninfected patients. These patients also had a higher 
prevalence of symptomatic carotid artery atherosclerosis [5].  Not only do HIV patients 
get cardiac events at younger ages and with more frequency, but their rate of disease 
progression is also worse. The rate of progression was not reversed in 121 HIV patients 
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with a follow-up measurement 1 yr later using CAC and CIMT as predictors of CVD risk 
in HIV patients [6]. For these comparisons, carotid IMT was found to be better capable of 
detecting subclinical atherosclerosis in patients with HIV after analyzing 258 HIV 
infected patients. Therefore, using CIMT as a lens to visualize cardiovascular disease 
progression in HIV patients, multiple reports have portrayed how cardiovascular health is 
not restored simply by bringing viral loads back to normal using ART. 
Using CIMT to study the progression of cardiovascular health in 166 HIV 
patients, Fitch et.al found an interesting interaction between smoking, age and HIV 
infection [7]. Increased CIMT was associated with smoking burden and age to a greater 
degree among HIV-infected vs. HIV-uninfected participants. These patients also show 
evidence of arterial stiffening. In another study following the progression of CIMT 
amongst 63 HIV patients showed that in addition to CIMT, arterial stiffness markers like 
carotid compliance were also heightened when compared to control (P<0.01) [8]. A 
similar study using echocardiography to study 77 HIV infected men observed elevated 
CIMT. But they also observed arterial stiffness as measured by looking at distensibility 
and compliance in brachial, femoral and carotid arteries [9]. Another study of 105 HIV 
infected patients also observed reduced ascending aortic distensibility when compared to 
controls [10].nThis increased risk of developing cardiovascular diseases was also 
observed in HIV infected children. Both left and right common carotid artery IMT, and 
left and right internal carotid artery IMT were significantly higher in the HIV infected 
children [11].  
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1.3 Cardiovascular diseases in patients on ART 
Given all evidence that there is an independent role of HIV infection as a risk 
factor for CVD development it would be interesting to know this increased risk is altered 
when patients were successfully treated with ART. In the following I will provide an 
overview addressing CVD risk in HIV patients on ART.  
There remains the need to study possible sources of vascular dysfunction in HIV 
patients because bringing viral replication under control using ART is insufficient to 
normalize the increased risk of developing vascular disease. Volpe et al could show in a 
6-year long longitudinal study with 211 patients that CIMT and CAC progression 
continues to worsen in the HIV infected population even after bringing viral replication 
under control by using anti-retroviral therapy [12]. A larger study of 389 HIV infected 
patients showed that at baseline levels HIV patients had elevated levels of carotid intima-
media thickness (CIMT) when compared to uninfected controls [13].  
Even the immediate prescription of anti-retroviral therapy upon diagnosis does 
not help alleviate all of the increased risks for CVD development in HIV patients. 
Analysis of vascular health from the Strategic Timing of Anti-Retroviral Therapy 
(START) trial shows a possible link between systemic inflammation and vascular health. 
An analysis in HIV patients on ART with preserved CD4+ counts showed a strong 
correlation between high levels of IL-6 and C-reactive protein in patients with impaired 
small arterial elasticity [14].  
In fact, patients from a wide variety of demographics display this increased risk of 
developing cardiovascular diseases. The incidence of cardiovascular disease like stroke 
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and transient ischemic attack (TIA) was determined in patients living with HIV in the 
AIDS Clinical Trials Group after ART therapy initiation [15]. In this cohort, women and 
non-Hispanic blacks were shown to have the highest incidence of stroke and TIA 
showing that these at risks groups need to be closely monitored. Another interesting 
observation was that at lower ages, women had a higher risk of developing stroke/TIA 
while at older ages, men had a higher incidence of stroke/TIA.  The interplay between 
age and sex in determining cardiovascular health in HIV patients remains unexplained. 
Even young, asymptomatic women with HIV infection (n=60) were shown to have higher 
amounts of noncalcified coronary plaque and inflammatory monocyte activation 
measured through both levels of soluble CD163 and the percentage of intermediate 
CD14+CD16+ monocytes. [16] 
Together, these studies from several groups worldwide paints a picture where 
HIV patients have elevated the risk of developing cardiovascular diseases even placed on 
anti-retroviral therapy and demonstrate good viral control. Not only do these patients get 
sicker at a younger age and are more likely to develop CVD, but the rate of progression 
of this risk is also not abrogated with ART initiation. 
HIV patients also suffer from other diseases affecting the vasculature suggesting a 
global source of vascular stress in this patient population. A study of 40 HIV infected 
men on ART evaluated their forearm blood flow [17]. These patients had impaired 
microcirculation as evidenced by lower maximal and percentage (%) change in forearm 
blood flow than control patients. HIV patients also had a higher prevalence of peripheral 
arterial disease as measured through brachial artery index <0.9 [18] in a study of 908 HIV 
infected patients and 11,106 controls. Another study looked at 122 older (>50yrs) HIV 
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patient cohort on ART and found an elevated prevalence of hypertension (54% vs 38%), 
hypertriglyceridemia (51% vs 33%), low bone mineral density (BMD) (39% vs 0%), and 
lipodystrophy [19]. A study in an Italian cohort of 1229 deceased HIV+ patients found an 
abnormally high rate of circulatory disease associated mortality [20]. Amongst the 
leading cause of death were diseases such as hypertension and ischemic heart disease. 
This elevated risk of cardiovascular disease development appears to be independent of 
viral load or the impact of antiretroviral therapy drugs.  
Elite controllers are HIV patients who are capable of mounting an immune 
response against the virus and therefore do not need ART to control viral replication. 
Hence, these patients are a good group to evaluate whether HIV infection in the absence 
of confounding factors like ART regimen could contribute towards HIV associated 
cardiovascular diseases. Pereyra et.al found an increased prevalence of atherosclerosis 
(78 vs. 42%, P < 0.05) and markers of immune activation in elite controllers compared 
with HIV-negative controls. Similarly, the monocyte activation marker - sCD163, was 
increased in elite controllers compared with chronic HIV-1 (P < 0.05) and compared with 
HIV-negative controls (P < 0.05) [21].  
The endothelium lines the inside of blood vessels and plays an important role in 
regulating proper vascular function. In this regard, HIV associated increased risk of 
developing vascular diseases displays a strong endothelial dysfunction component. Even 
in patients with well-controlled viremia after an extended time (12 years) of anti-
retroviral therapy administration, HIV patients had elevated markers of endothelial 
dysfunction [22] characterized by endothelial stress markers like β2-microglobulin, IL-8, 
TNFα, and sICAM-1 when compared to HIV uninfected healthy controls. Another study 
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of 52 patients who had a cardiac incident and enrolled in NIH clinical protocols; 
identified D-dimer, soluble vascular cell adhesion molecule-1, tissue inhibitor of 
metalloproteinase-1, and soluble tissue factor as predictors of CVD risk [23]. However, 
HIV associated variables were unable to predict CVD risk. 
1.4 Pulmonary diseases in HIV patients on ART 
Assuming that infection with HIV impairs the immune system including the one 
responsible for the clearance of lungs, it is not surprising that  HIV patients with COPD 
develop various pulmonary infections including community-acquired pneumonia (CAP), 
pulmonary tuberculosis (TB), and Pneumocystis jirovecii pneumonia (PCP) at a higher 
rate [24]. However, HIV patients were found to have a higher risk of developing a 
multitude of pulmonary diseases not specifically related to opportunistic infections. 
Using the Multicenter Aging Cohort (907 HIV-infected and 989 HIV-uninfected 
participants) and the Women's Interagency HIV Study (1405 HIV-infected and 571 HIV-
uninfected participants) found that HIV patients were at a higher risk for developing 
dyspnea, cough, wheezing, sleep apnea, and incident chronic obstructive pulmonary 
disease [25]. This risk disregards the route of HIV infection since a study looking at 
perinatally HIV+ patients, HIV infection decreased the ability to reverse restrictive 
diseases like asthma and developed emphysema at a younger age [26]. HIV infection not 
only increases the prevalence of disease but also worsens outcomes. A study looking at 
178 patients with Acute Respiratory Distress Syndrome showed that HIV-1-infected 
subjects were developed ARDS at an earlier age, had higher rates of asthma, chronic 
obstructive pulmonary disease, and pneumonia. These patients also had greater illness 
severity and marginally elevated but not significant hospital mortality rates [27]. 
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Furthermore, HIV infection increases the risk of development of pulmonary 
diseases with a vascular component. Pulmonary hypertension is a rare disease of the 
pulmonary vasculature characterized by vascular remodeling of the small vessels in the 
lungs. Endothelial dysfunction and hyper-proliferative smooth muscle cells result in 
occlusions of small vessels that lead to high pulmonary pressures and eventually diseases 
of the right ventricle. This disease shows an enhanced prevalence in patients already 
suffering from diseases like scleroderma and HIV. A meta-analysis of three studies in 
Africa estimated the prevalence of pulmonary hypertension to be 14% in their HIV 
patients which is dramatically elevated from the global prevalence of pulmonary 
hypertension at 15 in one million [28]. When pulmonary arterial pressures were estimated 
in 220 asymptomatic HIV patients [29] showed that elevated pulmonary pressures could 
be determined in 0.45% of the patients studied. A more thorough evaluation of 
pulmonary artery pressures in 2,831 HIV-infected and 5,465 HIV-uninfected veterans 
from the veterans aging cohort using echocardiography showed an elevated prevalence of 
increased pulmonary arterial pressures. Furthermore, these patients with pressures 
>40mm Hg showed increased mortality [30].  A similar approach in a German cohort of 
374 HIV+ patients showed the prevalence of PH as determined by echocardiography to 
be 6.1% compared to the earlier estimate of 0.45% [31]. This elevated risk for PH was 
also seen in 79 patients under the age of 16 who were HIV infected by horizontal transfer 
[32]. In this study, 23% of the patients analyzed had elevated mean pulmonary arterial 
pressures. Most patients had right ventricular hypertrophy and left ventricular 
hypertrophy but only 11% displayed left ventricular dysfunction. 
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Not only do HIV patients develop pulmonary hypertension at much higher rates, 
but the disease is also more severe. A comparison of 27 HIV positive pulmonary 
hypertension patients and 115 HIV- pulmonary hypertension patients showed that HIV 
patients had significantly lower ejection fraction and more patients had late-stage 
ventricular dysfunction [33]. Furthermore, HIV infection was associated with higher 
levels of inflammatory cytokines and the vasoconstrictor endothelin 1 [34]. In fact, 
Endothelin-1 levels were highest in the HIV patients who developed pulmonary arterial 
hypertension suggesting HIV's capacity to induce endothelial damage and alter 
functionality. This association was confirmed in an independent study that measured 
pulmonary arterial pressures using both echocardiography and right heart catheterization 
[35]. Elevated plasma endothelin 1 levels were shown to correlate with elevated mean 
pulmonary arterial pressure.  
In addition to pulmonary hypertension, HIV patients are also at a higher risk of 
developing COPD/emphysema, a progressive disease characterized by non-reversible 
loss of microvasculature. Using the large veterans aging cohort, 1428 HIV-infected and 
2104 uninfected patients with at least one acute exacerbation of COPD were analyzed 
[36]. Not only did HIV patients have increased the risk of developing COPD, but HIV 
infection also increased elevated the effect of cigarette smoking towards COPD 
development. Furthermore, HIV infected patients had increased emphysematous changes 
as measured using pulmonary function tests and fibrosis [37]. While fibrosis was 
associated with viral loads and CD4 counts, emphysematous changes were not correlated 
to viral load or CD4 cell counts and the increased risk persisted even in the patients on 
ART with undetectable virus. Therefore, HIV infection also increases the risk of 
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developing pulmonary diseases with a vascular component like COPD/emphysema and 
pulmonary arterial hypertension. 
2 HIV Nef: Virally encoded accessory protein 
2.1 Nef Persistence in HIV+ patients on ART 
Negative factor (Nef) is a Human Immunodeficiency Virus (HIV) virally encoded 
protein that plays an important role in facilitating and enhancing viral replication and 
immune evasion. A protein like Nef that is capable of hijacking multiple host cell 
signaling pathways is a leading candidate for contributing to vascular dysfunction and 
endothelial damage that underlies various cardio-pulmonary vascular diseases described 
earlier. Especially in the era of anti-retroviral therapy where the majority of HIV+ 
individuals are placed on anti-retroviral therapy regimen, the lack of HIV virus in the 
blood begs the question how HIV infection contributes to cardio-pulmonary vascular 
disease. Nef protein is a candidate since it persists in HIV patients on antiretroviral 
therapy with well-documented control of HIV viral replication.   
As early as 1989 anti-nef antibodies were detected in HIV-1-seronegative, viral 
antigen-negative, and virus culture-negative individuals [38]. This suggested the 
possibility that Nef antibodies could precede seroconversion and the presence of anti-nef 
antibodies could serve as a marker for early activation of proviral protein activity during 
latency. Nef protein persistence during viral latency itself could contribute to viral 
replication since Nef protein was able to stimulate HIV replication in latently infected 
MOLT-20-2 as well as U1 cells by altering cell signaling [39]. Similarly, Nef containing 
extracellular vesicles were also capable of promoting HIV-1 viral replication in quiescent 
11 
CD4+ T cells which were latently infected with HIV through an ADAM17 dependent 
mechanism [40].  
Given this benefit to persistent Nef protein for HIV viral production even during 
latency, Nef protein was detected in peripheral blood mononuclear cells of both 
treatment-naive HIV patients as well patients on antiretroviral therapy with undetectable 
viral load [41]. This persistence can be attributed to the presence of Nef protein inside 
CD45+ extracellular vesicles in the plasma of HIV infected individuals [42]. 
Extracellular vesicles can be readily taken up by a variety of cells and could act as the 
mode of dissemination of Nef in cells throughout the body.   
Furthermore, these Nef containing extracellular vesicles are capable of damaging 
cells that end up taking in these vesicles. Multiple studies have shown the pathogenic 
potential of these vesicles. Nef containing extracellular vesicles (EV) were isolated from 
HIV patients with HIV associated dementia was capable of produce Aβ secretion from 
neural cells [43] suggesting a pathogenic role for these EV. These Nef EV are capable of 
potently creating a pro-inflammatory environment. Addition of Nef EV to peripheral 
blood mononuclear cells led to TNFα converting enzyme (TACE) packaging into vesicles 
and subsequent secretion [44]. This Nef-induced TACE release was mediated in a 
paxillin/Pak2 dependent fashion and is of particular importance since TACE cleaves 
transmembrane TNFα to produce soluble TNFα that can, in turn, promote endothelial cell 
death and inflammation by interacting with its receptor TNFR1. Subsequently, Nef and 
TACE containing extracellular vesicles were isolated from HIV patients and this in turn 
correlated with immune pathogenesis in chronic HIV infected patients [45]. Uptake of 
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these Nef containing EV induced intracellular TNF cleavage by ADAM 17 and 
subsequent trafficking of TNF into endosomes which were eventually released [46].  
Since Nef is capable of hijacking host cell machinery, Nef is capable of exploiting 
multiple signaling pathways to alter vesicular trafficking and protein trafficking in the 
host cells where Nef is taken up. In this regard, Notch1 signaling was shown to play an 
important role for the endosomal trafficking of ADAM17 that precedes Nef-induced TNF 
release [46]. Another signaling mechanism important for Nef-induced TACE release was 
Hck kinase which was isolated in Nef containing EV isolated from HIV patients. 
Furthermore, Nef containing EV showed protein signature reminiscent of hepatocytes 
suggesting that the liver could act as a site for Nef trafficking and packaging during viral 
latency [47]. 
Nef protein can be secreted in extracellular vesicles not only from HIV infected 
leukocytes but also from a variety of cell types. HIV infected astrocytes as well as Nef-
expressing HeLa cells released Nef in the form of extracellular vesicles [48]. This 
suggests that Nef protein can independently mediate its own transfer into extracellular 
vesicles in the absence of other viral protein and infection. These Nef containing 
extracellular vesicles were toxic to surrounding cells as bystander CD4 T cells that 
absorbed these Nef containing extracellular vesicles become apoptotic [49]. 
Surprisingly, in a study looking at 134 HIV infected patients with well 
documented viremic control and undetectable HIV RNA, Nef protein in extracellular 
vesicles were detected in more than half the patients on antiretroviral therapy as well as 
in elite controllers [50]. This suggests that Nef protein persists at a much higher 
frequency than previously believed. As a result, Nef protein, specifically in extracellular 
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vesicles becomes an intriguing candidate to emerge as the driver for endothelial damage 
even in patients with undetectable viral particles. 
2.2 Nef interacts with and hijacks host cell signaling pathways 
In addition to the signaling mechanisms used by Nef to alter vesicular signaling 
pathways highlighted earlier, Nef has been shown to activate various kinases and 
miscellaneous signaling proteins in the cell. Most studies were characterized in the 
context of HIV infectivity and how Nef protein modulating host cell signaling enhances 
viral infectivity. Harada et.al described the importance of Nef towards replication 
potential of HIV and Simian Immunodeficiency Virus. [51] They created a short-lived 
Nef by fusing Nef sequence to a proteasome-mediated protein degradation sequence. As 
a result, cells infected with short-lived Nef containing HIV had lower levels of Nef which 
was restored upon addition of a proteasome inhibitor. Using this model, they found that 
short-lived Nef expression significantly reduced infectivity of HIV-1 when compared to 
WT Nef. Furthermore, the addition of both short-lived Nef and WT had a comparable 
increase in infectivity of SIV mac239.   
2.3 HIV-Nef alters packaging of host and viral proteins into virions and 
extracellular vesicles  
As a viral protein, Nef interacts with and hijacks host cellular signaling in order to 
facilitate HIV replication. By altering cellular trafficking and packaging, Nef promotes 
the formation of viral particles. Cornall et.al [52] showed the importance of Hck kinase in 
Nef-mediated increase in viral infection in both T cells and macrophages. Nef was shown 
to interact with HCK kinase using its SH3 binding domain containing the polyproline 
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motif – PxxP. Nef-Hck interaction facilitated the packaging of Hck into HIV virions 
which promoted HIV infection into T lymphoblasts.  
Bregnard et. al used a proteomic approach to study how Nef expression alters 
protein cargo in virions to modulate infectivity.[53] Specifically, they identified Ezrin 
and EHD4 as proteins that are differentially expressed in WT virions versus Nef deleted 
virions. This suggests that Nef expression enhance virus infectivity by modulating virion 
cargo with active packaging of host proteins that are beneficial to HIV infection. 
Furthermore, Nef interaction with host cell proteins also increases viral replication 
efficiency. Another host protein modulated by Nef [54] is Protein Kinase C (PKC). They 
found that Nef was phosphorylated by PKC in its N terminus at residue 6. This 
phosphorylation was important for Nef myristoylation and PAK2 activation. PKC 
modulated phosphorylation of N-terminus of Nef was important for the Nef-stimulated 
HIV transcription and replication in resting PBMC.  Qi et.al identified that Nef protein 
interacts with host protein cyclophilin A [55]. This cyclophilin A – Nef complex 
enhanced viral infectivity by its incorporation into virions via association with Gag 
during particle assembly. Similarly, [56] Schiavoni et.al found that Nef directly interacted 
with viral envelope protein env using residue 180-210 in the C terminus. This interaction 
occurred at the membrane and facilitated packaging of viral surface protein env into HIV 
viral particles to further enhance infectivity. 
Not only does Nef enhance packaging of viral proteins into viral particles, but it is 
also capable of enhancing infectivity of particles released by altering its surface 
characteristics optimal for infection. Zheng et.al suggested the role of lipid rafts as a 
mechanism through which Nef enhanced viral infectivity. [57] They show that HIV 
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virions from nef-deleted virus showed decreased infectivity and reverse transcription 
when compared to WT HIV. Nef was important for increasing viral particle budding from 
lipid rafts which are microdomains on the plasma membrane rich in sphingolipids and 
cholesterol. Nef also increased the amount of ganglioside which is a major component of 
lipid rafts. This Nef-induced increase in virion infectivity was reversed when lipid rafts 
were disrupted in cells.  
Another strategy used by Nef is to enhance the release of viral particles is through 
modulation of multivesicular body formation that is crucial for the release of viral 
particles. Costa et.al found that Nef binds to AIP1 which is an important player in the 
formation of multivesicular bodies [58].  Subsequently, Nef was able to increase the 
number of viral particles released but only when it was able to interact with AIP1. 
Therefore, Nef modulates multivesicular body formation to enhance egress of HIV 
virions from infected cells. 
This ability of Nef protein to modulate pathways governing vesicular transport 
and release is independent of whether a cell infected by the HIV virus. In the context of 
aviremic HIV+ patients on ART, Nef persistence has implications on the content and 
amount of extracellular vesicles released.  
2.4 HIV-Nef helps the virus with immune evasion 
Another mechanism through which Nef is important for HIV infectivity is by 
aiding HIV to evade the host immune system. The presence of Nef is capable of 
impacting multiple host immune cell types to either deplete the immune system or 
impede recognition of infected cells by immune cells. 
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Nef’s ability to enhance HIV infectivity through immune evasion was shown by 
Zou et.al using the BLT mouse model [59]. While inoculation with LAI strain of HIV 
produced 8,200,000 ± 1,800,000 copies of viral RNA/ml, inoculation with Nef deleted 
LAI stain of HIV only produced 1,220,000 ± 330,000 copies of viral RNA/ml. 
Furthermore, the WT strain of HIV efficiently depleted CD4+ T cells and CD4+ CD8- 
thymocytes which did not happen in the Nef deleted LAI strain. In the same BLT 
humanized mouse model, infection with JRCSF strain of HIV exhibited progressive loss 
of CD4 T cells in blood, bone marrow, spleen, lymph node lung and liver [60]. While the 
Nef deleted JRCSF virus had comparable peak viral loads, no loss in peripheral blood 
CD4 T cells was observed. Furthermore, the WT JRCSF virus induced a dramatic rise in 
activated CD8 T lymphocytes which was absent in the nef-deleted virus suggesting that 
Nef plays an important role in eliciting activated CTL response that could lead to CD4 T 
cell loss that precedes progression to AIDS.  
In order to characterize cellular signaling pathways that play an important role in 
Nef’s ability to impede the immune system, Pak2 kinases appear to a prominent cellular 
signaling axis. Nef-induced Pak2 activation was important for CD4 T cell lymphopenia 
as well as thymic depletion of CD4 T cells by HIV and Nef [61]. Nef-induced Pak2 
activation was also important for CD3 downregulation which dramatically reduced 
thymic output contributing to a weakened immune system that facilitates HIV 
pathogenesis. 
In addition to impacting CD4 T cells, Nef is capable of impacting other cell type’s 
surface markers as well. In order to promote immune evasion, Nef was able to modulate 
cytotoxic T lymphocyte response [62] as Chen et.al showed that Nef-mediated HLA-I 
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downregulation of CD8+ T cells reduced the kinetics of infection clearance and 
facilitated viral immune evasion. In order to do this, Nef downregulates CD155 which is 
a ligand recognized by the receptor DNAM-1 expressed by natural killer cells and CD8+ 
T cells[63]. Nef also downregulates NKGD2 to further enhance the immune evasion of 
HIV infected cells. These effects were conserved between multiple lab strains of HIV as 
well as a patient-derived sequence of Nef. Cd1a expression in dendritic cells is important 
for antigen presentation. Nef downregulates Cd1a in both natural killer cells as well as 
dendritic cells via activation of Hck and Pak2 [64]. This Nef-induced Cd1a 
downregulation facilitates HIV infection and subsequent cell death of these mediators of 
innate and adaptive immune systems. Nef also impacts B cells [65] as Swingler et al 
show that hyper-gammaglobulinemia and B lymphocyte hyperactivation is seen in HIV-1 
infection are attributable to Nef. Nef-expressing macrophages as well Nef + T cells were 
able to activate NF Kappa B mediated B cell activation which in turn lead to the secretion 
of B cell activation factor ferritin.  
In addition to the impacting the cellular compartments of the host immune 
system, Nef is also capable of affecting the acellular component of our immune system. 
Since Nef does transfer to B cells [41] and is capable of preventing IgG class switching 
[66], this arises as a strong possibility. Lai et.al questioned whether Nef effects the ability 
of neutralizing antibodies to counter HIV infectivity through the detection of HIV 
envelope protein, env [67]. They tested two potent neutralizing monoclonal antibodies, 
2F5 and 4E10 that target the membrane proximal external region of Env. Nef increased 
resistance to both neutralizing antibodies by up to 50 fold suggesting another ability of 
Nef to enhance HIV viral infectivity and immune evasion. 
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By affecting multiple arms of the host immune system, Nef is able to allow HIV 
infected cells to evade immune responses. Furthermore, this has implications for latent 
HIV infection since depletion of host immune system eventually aids HIV to break out of 
latency and promote viral replication. 
2.5 HIV Nef downregulates surface expression of receptors 
HIV Nef potently modulates the surface expression of various proteins to enhance 
immune evasion of HIV infected cells. As an early response gene, Nef can begin 
downregulating receptors even before HIV integration takes place. Sloan et.al infected 
cells with HIV but blocked integration using integrase inhibitor raltegravir [68]. HIV 
cDNA, even without integration was capable of downregulating MHC I, HLA-A, HLA-
B, HLA-C, HLA A31, and HLA E. Therefore, it is possible that the early response gene 
Nef provide one mechanism to facilitate immune evasion even in today's era of ART 
where integrase inhibitors are used as the first line of defense prescribed to patients.  
In this regard, Nef classically downregulates CD4 in by directly facilitating the 
formation of AP-2 mediated clathrin-coated pits [69]. Nef interacts with AP2 (σ2) using 
the hydrophobic region in the Nef C-loop with dileucine motif and the M168L170 motif 
and AP2 (α) using the acidic motif E174 and D175 [70]. Similarly, Nef downregulates 
CD36 in macrophages which corresponds to a decrease in oxidative burst capacity and 
ability to scavenge both GFP beads and GFP-expressing Salmonella tiphymurium [71]. 
This effect might not only help HIV to evade the innate immune system but also help 
explain the risk of opportunistic infections in HIV patients due to the weakening of the 
innate immune system.  
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In order to downregulate CD4, Nef dimerization appears to be an important first 
step [72]. Nef dimers were potently trafficked to the plasma membrane and the Golgi 
network, subcellular locations critical for Nef functionality. Dimerization defective Nef 
mutants had severely diminished CD4 downregulation capacity. Subsequently, HIV 
containing these dimerization defective Nef mutants also had lower replicative potential. 
Comparable replication potential between Nef deleted HIV and dimerization 
defective Nef mutant containing HIV suggest that Nef dimerization is an important first 
step for Nef enhanced HIV infectivity.  Two other motifs implicated in the Nef-induced 
CD4 and MHC-I downregulation are the ubiquitination K144 residue and the N-terminal 
tyrosine motif Y28Y39 [73]. Point mutations in either residue dramatically reduced Nef’s 
ability to reduce surface expression of CD4 and MHC-I via upregulation receptor 
endocytosis. While the polyproline rich SH3 binding domain of Nef is important for a 
wide variety of its functionality, [74] Kuo et.al describe that overlapping domains to 
flanking the PxxP motif also play an important role in the regulation of Nef-mediated 
host cell hijacking.  Logically, mutations to the PxxP motif blocked Nef-induced CD4 
and MHCI downregulation in addition to enhanced viral infectivity and Pak2 activation. 
However, they identified G67, F68, P69 to the C terminus of PxxP and the F90 to the N 
terminus of PxxP were also important for Nef functionality. 
There also appears to be variation in Nef’s ability to downregulate receptors like 
CD4 between different clades of HIV-1. A study by Mann et.al [75] postulates a 
functional hierarchy for Nef-mediated CD4 and HLA class I downregulation. They 
suggest that Nef from subtype B has the greatest ability to downregulate CD4 followed 
by clade A/D and finally C.  
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The importance of Nef in HIV-1 infectivity can be gleaned by taking a look at the 
Nef sequence alleles in the HIV infected elite controller population. These patients are 
uniquely capable of mounting a strong response against HIV and limit viral replication 
without the aid of anti-retroviral therapies. A study by Mwimanzi et. al[76] characterized 
the ability of 91 Nef clones, isolated from plasma of 45 elite controllers and 46 chronic 
progressors to down-regulate HLA class I and CD4, up-regulate HLA class II invariant 
chain (CD74), enhance viral infectivity, and stimulate viral replication in PBMC. They 
found that while Nef in elite controllers had lower functionality in all five parameters 
tested when compared to Nef isolated from the chronic progressor population. In a 
similar study, Corro et.al compared 10 long-term non-progressors and 6 rapid progressors 
[77]. They found that 40% of long-term non-progressors had defective Nef alleles in their 
ability to downregulate MHC I and CD4. Most substitutions were seen in two domains in 
this small patient cohort – AWLEAQ (56-61)) and the Rxx(22-24)) domains. 
Specifically, they identified the Nef L58V substitution as being associated with a 
reduction in HIV viral loads, persistent preservation of CD4 (+) T cell counts, and lack of 
AIDS-related symptoms. Cruz et.al also corroborated these findings in their cohort when 
comparing Nef sequences from normal progressors to slow progressors [78]. Slow 
progressors had a variety of deletion in the c terminus of Nef, which decreased Nef 
activity in T cells. Hence they suggest that Nef is a progression factor towards AIDS. 
Furthermore, specific point mutations characterized as a nef “allele” seems to be 
important for progression towards AIDS. A study by Meribe et.al found over-
representation of an Ile20 allele in their HIV patient cohort when compared to the Los 
Alamos database where met20 is the common amino acid [79]. Interestingly, when the 
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met20ile mutation was introduced in the SF2 Nef strain, they observed an enhanced 
HLA-I surface downregulation capacity in vitro. In support of this finding, patients with 
Ile 20 mutation had statistically significant higher plasma viral load suggesting naturally 
occurring Nef polymorphisms that support enhanced HIV pathogenicity. In support of 
this, Iijima et.al describe that tripartite hydrophobic motif (Trp13/Val16/Met20) in the N 
terminus of Nef functioned as a noncanonical mu-1A-binding motif for the interaction 
with the tyrosine motif-binding site of the mu-1A subunit to Nef [80]. Another domain 
was identified by Meuwissen et.al when they discovered a highly conserved valine-
glycine-phenylalanine (VGF) Nef allele from clinical isolates of HIV [81]. This VGF 
motif linked an acidic cluster to polyproline motif. Mutation of this motif in lab strains of 
HIV like NL4.3, NA-7 ad SF2 to AAA disrupted Nef’s ability to downregulate MHC-I 
and CXCR4, activate PAK2 to deregulate cofilin-mediated actin remodeling, target Lck 
to the trans-Golgi network to disrupt TCR signaling and bind to the Hck using the 
polyproline motif. Subsequently, this motif was also important for Nef enhanced HIV 
infectivity and replication. 
Therefore, in the heterogenic HIV infected population, various Nef alleles could 
contribute towards disease progression towards cardiovascular diseases. By studying 
consensus Nef sequences as well as lab strain HIV derived Nef, we can elucidate the 
common pathways through which Nef can impact cells that take up Nef. In contrast, Nef 
mutants capable of altering specific signaling pathways can serve as a tool to tease apart 
the hierarchy of signaling mechanism implicated in Nef-induced cell stress. 
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2.6 HIV Nef interacts with host cellular kinases 
As a small 27kDa protein, Nef has no known enzymatic function. However, it is 
potently capable of hijacking host signaling proteins in order to modulate cellular 
function. Using its polyproline rich PxxP motif, Nef binds to the SH3 domains of SRC 
kinase family members to facilitate MHC-I downregulation and improve viral infectivity 
and replication [82]. Similarly, allelic variants of Nef isolated from a variety of HIV-1 
subtypes was potently able to interact with TEC family kinases including Bmx, Btk, and 
Itk. This Nef-induced ltk activation was also shown to play an important role in 
enhancing viral infectivity and replication. 
Nef is capable of potently altering T cell receptor signaling by modulating 
subcellular fractions of the master regulator Lck [83].  Nef transfers active Lck kinase 
signaling pools from the plasma membrane to the trans-Golgi network. Without Lck 
present at the plasma membrane, TCR signaling is downregulated. Instead, at the trans-
Golgi network, Lck activates Ras-Erk signaling to promote the secretion of IL-2 that in 
turn further enhances viral infectivity. In addition to the polyproline PxxP motif, [84] a 
GLG motif at amino acid 121-137 was shown to play an important role for Nef-induced 
Lck signaling related CD4 downregulation.  This domain is also implicated in Nef-
dependent optimal infectivity of HIV-NL4.3 virus. Another effect of Nef-induced 
modulations of Lck signaling is in CD4 T cell differentiation and development [85]. 
Using a transgenic mouse model that expressing Nef in CD4 cells, Chrobak et.al showed 
that these mice develop CD4 T cell lymphopenia by depleting CD4+/CD8+ double 
positive thymocytes and blocking lineage commitment to CD4 single positive 
thymocytes. This effect was reversed upon constitutive activation of Lck. Hence Nef-
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induced changes in Lck signaling is an important mediator of HIV pathogenesis. Nef 
sequesters both Lck and Rac1 in a pericentrosomal compartment by altering the Rab 11 
mediated endocytic trafficking pathway [86]. In these signaling endosomes, downstream 
effectors of the Lck and Rac 1 were also identified TCRζ, ZAP70, SLP76, and Vav1. 
Nef-induced sequestering of Lck in Rab 11 endosomes altered T cell signaling and 
activation. On the other hand, Nef sequestering of Rac1 lead to reduced actin remodeling. 
This combination of Nef-induced Rac 1 and Lck sequestering potently alters T cell 
physiology. 
Another Src family kinase, Hck also interacts with Nef by creating a hydrophobic 
binding pocket using residues Ala 83, His116 and Try120. In fact, Tyr120Ile substitution 
completely abrogated Nef-induced Hck binding and activation.[87]. Upon Nef binding, 
the Hck 32L regulatory domain is was shown to display resonance changes as 
characterized by NMR studies [88]. Using hydrogen exchange mass spectrometry, Wales 
et. al [89] showed that the N-lobe of the kinase domain adjacent to the docking site for 
Nef on the SH3 domain is activated. This small conformational change is capable of 
enhancing viral infectivity and replication. Interestingly, a diphenylfuranopyrimdine 
kinase inhibitor DFP-4AB selectively inhibits Nef-dependent Hck activity blocks HIV 
replication. Such approaches provide an interesting avenue for future drug design that 
specifically targets Nef-induced kinase activity. 
Nef is also capable of activating the p21 activated kinase (Pak) 2 to modulate a 
wide variety of signaling pathways. Nef binds to Pak2 using small GTPases like CDC42 
and Rac and that Nef-induced Pak2 activation played an important role in functions like 
serum response pathway as well increased HIV-1 viral production. HIV-Nef has been 
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shown to bind to and activate Rac 1 signaling which plays an important role in ROS 
production and apoptosis [90-94]. As a result, Rac 1 signaling is emerging as a target for 
the development of cardiovascular therapies [95]. Recent studies have suggested the use 
of statins, HMG CoA reductase inhibitors, as a novel way to block Rac 1 signaling by 
inhibiting the geranylgeranylation of Rac 1 [96-99]In this regard, Raney et. al showed 
that Nef binding to Rac1 using the polyproline PxxP motif was crucial for  Nef-induced 
Pak2 activation [100]. Using a cell-free system, they showed that Nef from multiple lab 
strains was capable of activating Pak2 and that a point mutation in Phenylalanine 195 was 
capable of downregulating Nef-induced Pak2 activation. Endogenous GTPases like Rac1 
and Cdc42 were needed to transiently activate Pak2.   They also found that only a small 
fraction of Pak2 was associated with Nef and within the membrane-associated cell 
fraction. Interestingly, the presence of microsomal membranes was imperative for Nef-
induced Pak2 activation which is supported by how Nef-induced Pak2 activation occurs 
at the membrane. Furthermore, this Nef/Rac1/Pak2 axis did not require other adaptor 
proteins like Nck or Beta-Pix for Pak2 activation [101]. Agopian et.al noted that most 
studies disrupting Nef-induced Pak2 activation (G2, PxxP72, and RR105) also affect 
other Nef functions, such as CD4 or major histocompatibility complex class I (MHC-I) 
downregulation making it difficult to pinpoint Nef-induced Pak2 activation and its 
downstream effects. In this regard, they analyzed Nef alleles with preserved CD4 and 
MHC I downregulation that was important for Pak2 activation - L85, H89, S187, R188, 
and F191 [102]. All of these amino acids cluster on the surface of Nef in a domain that is 
different from the SH3 and dimerization and therefore forms a unique interaction motif 
for Nef-induced Pak2 activation. The 62EEEE65 acidic cluster domain is also important 
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for Nef-induced Pak2 activation as mutation to alanine also disrupted Nef-induced Pak2 
activation. [103] Similar to the endogenous furin protein, this acidic cluster stabilizes 
binding of Nef to Pak2’s furin binding region. 
Another consequence of Nef-induced PAK2 activation is the recruitment of the 
Exocyst complex protein EXOC1[104]. This interaction between Nef and EXOC was 
dependent on PAK2 activation and dependent on Rac1 binding using the PxxP motif. 
Nef-induced Exocyst activation modulated actin remodeling and impaired T cell 
trafficking capabilities. Downstream of Nef-induced Rac1 activation, PAK1 kinase is 
also modulated by Nef. This activation also leads to the formation of trichopodia, the 
activation of Jun N-terminal kinase, and the increase of viral production [105]. The 
ability of Nef to interact with two small GTPases, Rac1 and CDC42 and activate 
downstream kinases such as Pak1 and Pak 2 suggests a certain redundant capacity of Nef 
to hijack host cell signaling pathways. Furthermore, only a fraction of the kinases is 
signaling via Nef while the vast majority is involved in other pathways that are important 
for normal cell function. Therefore, identification of inhibitors based on studying Nef’s 
interactions domains with kinases that Nef activates like Lck and Src similar to the 
strategies employed for targeting Nef-Hck activation [89] could lead to a useful tool for a 
refined understanding of HIV-Nef signaling. 
2.7 HIV Nef induces production of reactive oxygen species 
The NADPH Oxidase complex helps in the production of reactive oxygen species 
(ROS) that regulates both physiological and pathophysiological functions. Nef drives an 
increase in ROS production by facilitating the recruitment of NADPH oxidase complex 
subunit p22phox [106]. Subsequently, Nef expression was capable of increasing 
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superoxide production in neutrophils by helping increase the rate of assembly of the 
NADPH oxidase complex. Further studies using in silico modeling and functional studies 
using Nef mutants showed that FPDW 121-124 on Nef is important for Nef-p22phox 
binding that leads to increased superoxide production [107]. 
Another subunit of the NADPH oxidase complex, p47phox was also found to be 
modulated by Nef expression [108]. Nef induced Src kinase activation followed by 
MAPK and ERK1/2 activation lead to translocation of p47phox into the plasma 
membrane. This translocation of p47phox to its site of action is an important precursor to 
Nef induced superoxide production in U937 monocytic cell lines. 
Nef induced increase in phagocytic oxidative burst capacity was further studied in 
macrophages transduced with Nef expressing lentivirus [94]. In this study, Nef was 
shown to utilize a vav/rac1/Pak2 signaling pathway since a constitutively active rac 
replicated Nef induced increase in superoxide production. Similarly, Nef mutants 
incapable of activating vav and Pak2 did not induce this effect providing further support 
for the role played by this signaling axis. Furthermore, the trafficking of Nef and NADPH 
oxidase complex proteins to the membrane, interaction of Nef with the endocytic 
machinery and subsequent activation of Rac1/Pak2 pathway were all shown to be 
important precursors for Nef induced superoxide release [109]. The small GTPase Rac1 
is well characterized binding partner of Nef using its polyproline PxxP motif and is also a 
component of the NADPH oxidase complex. In this regard, DOCK2-ELMO1 protein 
complex recruited by Nef to enhance Rac1 activation [90]. 
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2.8 Statin treatment blocks Rac1 activation 
While Nef signals by hijacking host cell signaling of the small GTPase Rac1, one 
major challenge remains with Rac1 inhibition. To suggest therapeutic agents to counter 
Nef induced vascular stress, it is of critical importance that the therapeutic agent are well 
tolerated and have a well characterized history. In this regard, statins have been used in 
clinical HIV studies and more importantly to combat hypercholesterolemia all over the 
world for decades. Statins block the production of cholesterol through inhibition of the 
mevalonate pathway, they also inhibit the production of isoprenoid intermediates in the 
cholesterol biosynthetic pathway. As a result, prenylation of Rac1, a post translational 
modification important for surface trafficking of Rac1 is affected [97]. In turn, 
downstream signaling of Rac1 like Rho kinase and NADPH oxidase complex assembly 
are also inhibited as a pleiotropic effect of statin treatment [110]. 
Paradoxically, while membrane bound Rac1 was dramatically downregulated 
with statin treatment of microglia, the amount of GTP bound Rac1 was found to be 
upregulated [111]. This could be attributed to the reduced interaction between Rac1 and 
its negative regulator Rho guanine nucleotide dissociation inhibitor (RhoGDI). Therefore, 
statin mediated alterations in Rac1 signaling is primarily due to subcellular location of 
Rac1 and not its functionality. 
Statin treatment of endothelial cells induced the translocation of small Rho 
GTPases from the cellular membrane to the cytosol, which was reversed by 100 µM 
mevalonate and 10 µM Geranyl Geranyl Pyrophosphates [99]. This shows that statin 
treatment, through inhibition of the mevalonate pathway depletes the pool of Geranyl 
Geranyl Pyrophosphates. In turn, this reduces the amount of membrane bound Rac1 
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where it needs to be in order to interact with myristoylated Nef. Furthermore, 
Atorvastatin’s capacity to block Rac1 activation and protect neuronal cells was dependent 
on activity of geranyl geranyl transferase 1β and depletion of geranyl geranyl 
pyrophosphatase.  [112] 
Similarly, studies in rat vascular smooth muscle cells showed that simvastatin was 
capable of inhibiting RhoA and Rac1 signaling which could be reversed using 
geranylgeraniol [113]. In this model, simvastatin interruption of Rac1 signaling resulted 
alterations to actin assembly and contractile function of smooth muscle cells.  
In THP-1 monocytes, lipopolysaccharide treatment resulted in Rac1 activation 
which could be blocked using pretreatment with 20μM mevastatin [114]. As a result, 
Rac1-PI3K complex formation was also inhibited suggesting that statin treatment of Rac1 
could affect another kinase downstream of Rac1.  
Another mechanism of statins pleiotropically inhibiting Rac1 activation is through 
the upregulation of small GTP-binding protein GDP dissociation stimulator (SmgGDS) 
[98]. SmgGDS silencing reduced the ability of statins to block rac1 activation and reverse 
Rac1 dependent ROS production. Furthermore, healthy subjects treated with statins 
showed increased SmgGDS expression levels along with a reduction in oxidative stress 
markers in vivo. 
In a Rat model with transgenic Renin expression upon which there is constitutive 
Renin-Angiotensin activation resulting in increased systolic blood pressure, albuminuria, 
renal NADPH oxidase activity, and 3-nitrotryosine staining [115]. Interestingly, 
Rosuvastatin treatment was able to reverse these phenotypic changes via downregulation 
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of NADPH oxidase complex subunits including Rac1 and p22phox. As a result, 
rosuvastatin was capable of downregulating NADPH oxidase mediated ROS production 
in both in vivo model and in vitro model of immortalized podocyte cell line. 
Similarly, angiotensin infused rats acetylcholine induced relaxation was impaired 
but reversed with both NADPH oxidase inhibition and anti-oxidant treatment suggesting 
a role of ROS production contributing to endothelial dysfunction [116]. Further studies 
showed that Angiotensin II increased intravascular ROS levels, induced eutrophic 
remodeling, collagen and fibronectin accumulation and finally resulted in elevated 
arterial stiffness. Treatment with rosuvastatin (10mg/kg for 14 days) blocked the 
elevation of phosphorylated p47phox, p67 phox and therefore lowered NADPH oxidase 
mediated ROS production. As a result, rosuvastatin treatment reversed angiotensin II 
mediated alterations in arterial resistance and function. 
In addition to angiotensin II mediated ROS production, Atorvastatin treatment 
was also able to alter NADPH oxidase activity in ApoE deficient mice fed a high fat diet 
[117]. The lower levels of ROS production in aorta was attributed to the impaired 
membrane translocation of Rac1 upon Atorvastatin treatment.  
Furthermore, Pitavastatin treatment was able to reduce angiotensin II induced 
ROS production, TGFβ1 secretion and smad2/3 phosphorylation [118]. This was 
mediated by Pitavastatin mediated downregulation of Rac1 activity resulting in protection 
from hypertension induced atrial remodeling. 
Similar effects of statin treatment on Rac1 mediated NOX dependent ROS 
production were also observed in a db/db murine mouse model of type II diabetes [119]. 
30 
In this model, NOX dependent ROS was elevated in plasma accompanied by elevated 
cytosol to membrane trafficking of NADPH oxidase subunits p47phox and Rac1 in the 
vessels. Interestingly, 2 week treatment of 10mg/kg Atorvastatin effectively reduced 
NOX dependent ROS production as well limiting the amount of membrane bound Rac1 
and p47phox. Atorvastatin treatment was also capable of reversing signaling downstream 
of ROS including VCAM-1 surface expression in aortas, phosphorylation of redox 
sensitive MAPK and pro-inflammatory NFκB signaling. Furthermore, Atorvastatin was 
capable of reversing acetylcholine induced vasorelaxation. 
Another diabetes model with impaired vascular function was Zucker fatty rats 
which had elevated angiotensin II mediated ROS production, endothelial dysfunction and 
reduced eNOS production [120]. However, Pitavastatin treatment was able to reverse 
these effects and restore normal vasodilation function by reducing NADPH oxidase 
activity as evidenced by lower gp91phox subunit localization in the membrane. 
Further support of Atorvastatin treatment being beneficial to endothelial cells was 
provided in TNFα treated human aortic endothelial cells. TNFα treatment promoted 
cytosol to membrane trafficking of Rac1 which resulted in increased NOX mediated ROS 
production [121]. As a result, these human aortic endothelial cells showed NFκB 
activation followed by increased expression of VCAM-1 and ICAM-1. Atorvastatin 
treatment potently reversed these effects as well as upregulated ERK5 activity which 
helps further inhibit endothelial cell activation. 
In canine models of tachycardia induced chronic heart failure, femoral blood flow 
responses to acetylcholine was impaired suggesting impaired vasodilations [122]. 
Congestive heart failure resulted in elevated vascular superoxide production and NADPH 
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oxidase activity due to increased membrane expression of NOX4 and p47phox. NOX4 
inhibitor apocynin and Pitavastatin treatment were capable of inhibiting ROS production 
and restoring acetylcholine mediated vasodilation. 
Pitavastatin treatment improved vascular function also improved heart function in 
rat model of hypertensive rats with heart failure [123]. 3mg/kg administration of 
Pitavastatin improved end systolic elastance and percent fractional shortening seen in rats 
with heart failure. Pitavastatin treatment reversed Rac signaling evidenced by ROCK 
kinase signaling resulting in reduced ROS production and reversing PI3K-Akt signaling. 
Statin treatment was even shown to be protective in pulmonary vascular diseases 
like pulmonary hypertension [124]. In the aortic banding model of for pulmonary 
hypertension secondary to left ventricular dysfunction, simvastatin at 30mg/kg was able 
to reduce mean pulmonary arterial pressure and pulmonary arterial remodeling. Further, 
simvastatin treatment reduced pulmonary expression of reactive oxygen species, the 
NADPH oxidase 2 regulatory subunits, p47phox and p67phox while increasing 
pulmonary expression of p-eNOS and cGMP. 
Vascular modeling in pulmonary hypertension is characterized by 
hyperproliferation of pulmonary arterial smooth muscle cells. The ability of stains to 
reverse vascular remodeling could also be attributed to its effect on smooth muscle cells. 
A study to determine the mechanism behind increased proliferation of smooth muscle 
cells induced by Lysophosphatidic acid (LPA), a by-product of LDL oxidation that is 
isolated from atherosclerotic plaques [125]. LPA dose-dependently increased NADPH 
oxidase mediated ROS production which was blocked using Pitavastatin treatment as 
well as overexpression of RacT17N dominant negative in aortic smooth muscle cells. 
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Furthermore, Pitavastatin treatment reversed LPA induced proliferation and MCP-1 
secretion by abrogation of ROS production. 
Pitavastatin treatment was also able to have a protective effect on the vasculature 
of chronic smokers [126]. In a study of 30 chronic smokers, Pitavastatin treatment 
showed significant restoration of endothelial function as measured by flow mediated 
dilation and oxidative stress levels quantified using malondialdehyde-low-density 
lipoprotein-cholesterol and free radical levels. These were only some examples taken 
from a wealth of literature on beneficial effects of stating in preventing vascular disease 
independent of its cholesterol lowering activity. 
3 Endothelial-monocyte activating polypeptide II (EMAP II) 
3.1 Induction of EMAPII 
Endothelial monocyte activating polypeptide II (EMAPII) was identified from the 
supernatant of murine methylcholanthrene A-induced fibrosarcomas based on its ability 
to activate endothelial cells [127]. The mature form was characterized as a 25 kDa 
protein based on SDS-PAGE of the purified protein and Western Blotting, but cloning 
predicted a smaller MW of ca 18kDa and a precursor protein of a predicted 34 kDa single 
polypeptide chain [128]. Addition of this purified and recombinant mature EMAPII to 
endothelial cells lead to increase in cytosolic free calcium, secretion of von Willebrand 
factor and expression of the adhesion molecules E-selectin and P-selectin suggesting an 
activated endothelial cell phenotype. Furthermore, the addition of purified mature 
EMAPII to neutrophils and mononuclear phagocytes increased cytosolic calcium 
concentration and stimulated chemotaxis. EMAPII delivery into mice resulted in 
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systemic toxicity, pulmonary congestion, and the appearance of TNF, interleukin-1 and -
6 in the plasma. The effects of EMAPII were due to an N-terminal binding site between 
residues 6-20 [129].  This peptide sequence was capable of inducing both cytosolic 
calcium release and peroxidase release in polymorphonuclear leukocytes. In vivo, 
injection of this peptide into the footpad of mice was capable of promoting migration of 
inflammatory cells. Therefore, release of mature EMAPII peptide can act as medium for 
cross talk between endothelial cells and inflammatory cells.  
However, EMAPII is generally found to be a part of the aminoacyl-tRNA 
synthetase complex and needs to be processed before it can have these effects. Mature 
EMAPII is released from the aminoacyl-tRNA synthetase complex after digestion by 
Caspase 7 indicating that mature EMAPII release is tightly associated with cells 
undergoing cellular apoptosis[130] [131].  In a physiological setting of embryonic 
development, association of EMAPII with cells undergoing apoptosis was also observed 
since EMAPII gene was also found to be upregulated around apoptotic cells in mouse 
embryo throughout development [132].  
Once it is cleaved and released, extracellular EMAPII acts as a ligand that binds 
to CXCR3 receptor based on blocking and binding studies using radiolabeled interferon-
gamma-induced protein (IP-10). This ligand-receptor interaction between EMAPII and 
CXCR3 was necessary for endothelial cell chemotaxis towards EMAPII gradient [133]. 
Furthermore, this interaction of EMAPII and the CXCR3 receptor in endothelial cells is 
also capable of inducing endothelial cell apoptosis in a p38 MAPK dependent fashion 
[134]. 
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Given these observations that the release of EMAPII is associated with a pro-
apoptotic, anti-angiogenic environment; multiple reports have identified EMAPII release 
associated with various disease states. As pertaining to HIV, Green et. al, showed that 
other HIV proteins can indeed upregulate EMAPII surface expression. HIV envelope 
protein GP120 binds to its receptor CXCR4, activates p38 MAPK signaling and induces 
surface expression of EMAPII in endothelial cells [134]. This gp120 induced EMAPII 
surface expression induces endothelial cell apoptosis which was reversed with EMAPII 
neutralizing mab. 
An important aspect of cancer signaling is immune evasion and since EMAPII is 
capable of damaging immune cells expressing the CXCR3 receptor, it would be 
interesting to evaluate whether EMAPII is upregulated in the setting of cancer. Elevated 
EMAPII levels were detected in the blood of colon cancer patients. Tumor-secreted 
kisspeptin was capable of inducing surface expression of EMAPII by activating G 
protein-Coupled Receptor 54. This Kisspeptin induced lymphocyte apoptosis could be 
neutralized using an EMAPII neutralizing ab [135]. Another possible regulator of 
EMAPII expression in tumors may be hypoxia. In this context, both EMAPII mRNA and 
protein expression is upregulated in TNFα fibrosarcomas and in B16 melanomas near 
areas of tissue necrosis [136]. These areas were shown to overlap with injected chemical 
indicators of hypoxia using confocal immunochemistry.  In support for the hypothesis 
that EMAPII is regulated by hypoxia, EMAPII expression was also found to be elevated 
in hypoxic and apoptotic tumor cells. Furthermore, EMAPII levels in the supernatant of 
hypoxic tumor cells were also elevated. In support of this, EMAPII mRNA levels were 
elevated in hypoxic endothelial cells and colon cancer cells like DLD-1 [137]. However, 
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normal colon cancer cells did not upregulate EMAPII transcription when exposed to 
hypoxia.  
Furthermore, EMAPII is also upregulated in diseases with an inflammatory 
component. 23 patients undergoing allogeneic stem cell transplantation therapy had 
elevated expression levels of EMAPII. Furthermore, EMAPII levels correlated with 
endothelial inflammatory markers like sIL-2R, sVCAM-1, sE-selectin, and sFasL [138]. 
This suggests EMAPII could contribute to Graft Vs Host disease in patients receiving 
stem cell transplantation. Looking at the gingival crevicular fluid from the mouth, 
EMAPII was shown to be upregulated in patients with generalized aggressive 
periodontitis when compared to healthy subjects or patients with just gingivitis [139].  
Furthermore, elevated EMAPII levels could act as a biomarker for vascular 
complications in disease states. When EMAPII serum levels were analyzed in 80 Type I 
Diabetic children with/without microvascular complications, patients with microvascular 
complications had the highest serum EMAPII levels (1539 +/- 321.5 pg/ml) followed by 
Type I diabetics without microvascular complications (843.6 +/- 212.6 pg/ml). Both Type 
I diabetes groups had higher serum EMAPII than healthy controls (153.3 +/- 28.3 pg/ml) 
[140]. Similarly, EMAPII upregulation is also witnessed in diseases involving damage to 
the endothelium. Following the percutaneous coronary intervention, EMAPII was 
upregulated in distal coronary artery segments [141]. Interestingly, oral rapamycin 
treatment was able to successfully downregulate surface EMAPII expression. 
Another mechanism of EMAPII upregulation was chronic cigarette smoke 
exposure. Mice exposed to cigarette smoke showed elevated levels of EMAPII protein in 
their bronchoalveolar lavage when compared to air control exposed mice.  This cigarette 
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smoke exposure induced EMAPII release was mediated by apoptosis is driven feed-
forward loop since inhibition of caspase 3 blocked EMAPII upregulation. [142] 
3.2 EMAPII: Cell death and anti-proliferation marker 
Given it’s associated with apoptotic cells and anti-angiogenic environments, extracellular 
EMAPII, either at the surface or when secreted can act as a cell death and anti-
proliferation marker. Studies in a wide variety of pathophysiological contexts have been 
conducted to describe these effects. 
Within the setting of tumor microenvironments, EMAPII’s anti-proliferative 
capacities were co-opted to try to fight back against tumor cells and enhance 
effectiveness of cancer drugs. Glioma stem-like cells (GSCs) are believed to provide drug 
resistance to chemotherapeutics like temozolomide (TMZ) in patients with glioblastoma. 
In this study by Yu et.al, EMAPII was able to enhance the cytotoxicity of TMZ, 
suppressed mTOR signaling, facilitated autophagy-mediated cell death as well as induced 
G2/M a cell cycle arrest [143]. Furthermore, the combination of EMAPII and TMZ 
downregulated miR-24a-3p which results in elevated levels of its target genes including 
Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) [144]. This EMAPII 
induced miR-24-a-3p downregulation resulted in elevated mitophagy, apoptosis, and 
impaired migration. EMAPII inhibited cell viability and decreased the mitochondrial 
membrane potential in both human glioblastoma cell and GSCs and served to increase 
effectiveness of rapamycin [145]. Upon EMAPII addition, autophagic vacuoles were 
observed. EMAPII also inhibited PI3K/Akt/mTOR signaling and induced mitophagy and 
ER stress in these cells. In combination with rapamycin, EMAPII synergistically 
inhibited cell proliferation, migration, and invasion of glioblastoma cells.   
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In pancreatic ductal adenocarcinoma (PDAC), EMAPII's anti-proliferative 
capacities on endothelial cells worked in combination with other front-line 
chemotherapeutic agents like gemcitabine and sorafenib by inducing endothelial cell 
apoptosis and enhancing survival from pancreatic ductal adenocarcinoma [146]. Even 
though EMAPII did not contribute towards killing PDAC tumor cells, EMAPII addition 
further enhanced median survival when given in combination with docetaxel-gemcitabine 
[147] or bortezomib-gemcitabine [148].In this regard, EMAPII reduced fibronectin 
production by PDAC. The interaction between fibronectin and integrin alpha3, alpha5, 
alpha6, and alphaV was crucial for tumor-associated vessel formation and endothelial 
proliferation [149].  Immune evasion of tumor cells is facilitated by EMAPII induced 
apoptosis of tumor invading lymphocytes [150]. In fact, hypoxia-exposed tumor cells not 
only showed increased surface EMAPII expression but also potently induced lymphocyte 
apoptosis. The role of EMAPII in facilitating cell death was used as a prognostic 
biomarker in cancer patients to track treatment response. Intralimb perfusion of TNF-α is 
used as a cancer therapeutic to limit tumor cell proliferation. High EMAPII levels in 
melanoma patients receiving intra-limb perfusion were found in patients showing 
complete tumor response. This EMAPII expression was seen in both melanoma cells as 
well as endothelial cells and macrophages near the tumor site [151]. EMAPII primes cells 
for TNF- α induced apoptosis by promoting the redistribution of TNFR1 from the Golgi 
to the cell membrane [152]. Furthermore, EMAPII promoted TNF- α mediated pro-
apoptotic signaling by increasing TNF-R1-Associated Death Domain (TRADD) protein 
recruitment to the cell membrane. Within 2hrs upon EMAPII addition, HUVECs also had 
elevated levels of TNF-R1. Similarly, the addition of conditioned media from tumor cells 
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secreting EMAPII also produced elevated levels of TNF-R1 but not TNF-R2 in HUVECS 
[153].  
3.3 EMAPII as a vascular permeability factor in tumors 
Lowered vascular permeability in the blood-brain barrier provides another avenue 
for drug resistance in brain tumors like glioblastoma. Chen at.al found miR-429 to be 
expressed at lower levels [154] in glioma vascular endothelial cells and that high-grade 
glioma had even lower expression levels. However, the addition of EMAPII to glioma 
endothelial cells increased expression of miR-429 which in turn lead to decreased 
expression of tight junction proteins including ZO-1, occludin, and claudin-5. 
Subsequently, EMAPII addition resulted in increased permeability as well as decreased 
transepithelial electrical resistance. Another miRNA regulating EMAPII mediated 
increased brain tumor vascular permeability was described to be miR-330-3p [155]. miR-
330-3p is also downregulated by EMAPII addition to Glioma endothelial cells which 
resulted in higher levels of its target PKC-α. PKC-α upregulation/activation results in 
lower levels of tight junction proteins like ZO-1, occludin, and claudin-5 in these cell 
types. 
In addition to miRNAs modulating EMAPII induced effects on cell signaling, 
small signaling GTPases also play an important role. While EMAPII increased blood-
tumor permeability in rat brain microvascular endothelial cells, the addition of RhoA 
inhibitor (C3 exoenzyme), as well as ROCK inhibitor, was capable of inhibiting this 
effect [156]. Similarly, these inhibitors also blocked EMAPII induced downregulation of 
tight junction proteins like occluding, ZO-1 as well as stress fiber formation mediated by 
phosphorylated myosin light chain and actin assembly protein cofilin. Upstream of 
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RhoA/ ROCK signaling, the cAMP/EPAC1/Rap1 signaling axis was also impacted with 
low dose EMAPII addition. Subsequently, elevation of cAMP levels with forskolin and 
Epac/Rap1 activation by 8-pCPT-2'-O-Me-cAMP reversed EMAPII induced rise in 
permeability [104].  
Furthermore, EMAPII was also shown to impact transcellular permeability since 
EMAPII addition to rat brain microvascular endothelial cells resulted in increased 
pinocytic vesicles observed via transmission electron microscopy [157]. Within 1h of 
EMAPII treatment, protein expression of caveolin-1, caveolin-2, p-caveolin-1, p-
caveolin-2, and p-Src were elevated. This suggests that using a tyrosine kinase-mediated 
pathway, EMAPII increases levels of phosphorylated caveolin proteins which in turn 
facilitates transcellular permeability.  
3.4 EMAPII neutralization as a therapeutic strategy for protecting the endothelium 
An anti-EMAPII rat monoclonal antibody was described by Rajashekhar et.al 
with the ability to neutralize both full length and mature EMAPII. This monoclonal 
antibody was named M7/1 and shown to detect EMAPII in western blot, to block 
migration of PBMCs towards EMAPII and ameliorate EMAPII induced tumor cell and 
endothelial cell apoptosis. [158]  Lung-specific overexpression of EMAPII in transgenic 
mice resulted in the simplification of alveolar structures, apoptosis of endothelial cells 
and accumulation of pro-inflammatory macrophages [142]. Similarly, cigarette smoke-
induced emphysema in mice was also accompanied by elevated EMAPII levels. 
Neutralizing antibodies targeting EMAPII reduced alveolar cell apoptosis, inflammation 
and emphysema-associated structural changes in alveoli and small airways as well as 
improved lung function. 
40 
In fact, cigarette smoke exposure also upregulated EMAPII’s receptor, CXCR3 in 
both human lung microvascular endothelial cell in vitro and murine lung endothelium in 
vivo. This receptor upregulation primed endothelial cells for EMAPII induced apoptosis 
which was effectively blocked by using neutralizing antibodies against the CXCR3 
receptor [159]. Furthermore, CXCR3 mediated endothelial apoptosis was dependent on 
p38 MAPK signaling. Furthermore, EMAPII was shown to be a key mediatory of Acute 
Lung Injury in the setting of murine Influenza A virus infection. Within this context, 
EMAPII neutralizing antibody was capable of blocking pulmonary epithelial and 
endothelial damage. [160]  
In addition to modulating pulmonary diseases, EMAPII was found to be elevated 
following cardiovascular diseases like myocardial infarction. Interestingly, treatment with 
a different EMAPII neutralizing antibodies after permanent coronary occlusion in mice 
leads to an improvement in survival rate, reduced scar size, and prevention of heart 
failure. The antibody treated group also showed decreased fibrosis, improved myocyte 
viability in the infarct area and increased capillary density [161]. 
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II Materials and Methods 
1 Tissue Culture 
Human lung microvascular endothelial cells (HMVEC) and Human Coronary 
Artery Endothelial Cells (HCAEC) were obtained from Lonza (MD, USA) (CC2527) and 
cultured in EGM-2MV. SupT1 and Nef-ER-expressing SupT1 cells were obtained from 
the AIDS Reagent repository and cultured in RPMI with 10% FBS. Jurkat T cells and 
human-derived PBMCs (Indiana Blood Center, IN, USA) were cultured in RPMI with 
10% FBS. HEK 293T were cultured in DMEM with 10% FBS. Primary alveolar 
macrophages were isolated from BAL fluid of healthy volunteers and cultured in RPMI 
with 10% FBS. 
2 Patient Enrollment and Consent 
13 HIV- healthy volunteers, 4 HIV+ patients on anti-retroviral therapy and 13 
HIV+ patients not on anti-retroviral therapy were enrolled after Internal Review Board 
approval and obtaining informed consent. PBMC was isolated from patient blood using 
Ficoll separation. Over 80 patients were enrolled as part of the Investigating HIV 
Associated Lung Disease (INHALD cohort) after Internal Board review. BAL derived 
cells and acellular BAL fluid was obtained from this study. 
3 Extracellular Vesicle Isolation and Characterization 
EV were isolated from acellular BAL fluid and supernatant of control/Nef 
expressing cells using ultracentrifugation .The number and size of the EV released was 
assessed by NanoSight (Malvern, UK). 
4 Detection of Secreted Cytokines 
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Cytokine levels in acellular BAL fluid of HIV patients and supernatants of 
alveolar macrophages and HIV-Nef transfected HEK 293T cells were measured using 
BD Cytometric Bead Array. 
5 Apoptosis Detection 
 Apoptosis was measured in HMVECs using Flexstation (Molecular Devices, 
USA) by detecting caspase 3 activity (APO Logix Caspase 3/7, Cell Technology, USA) 
and mitochondrial depolarization (JC-1 Ab113850, Abcam, USA). TUNEL staining was 
performed using Apo-BRDU apoptosis detection kit (88-6671-88, Thermo Fisher, USA) 
and analyzed using flow cytometry.   
6 Animals 
HIV-Nef transgenic mice containing the tetracycline (tet)-responsive element 
were crossed with the VE-Cadherin promoter controlled tet-off-transactivator mouse line 
[24] and housed at the Indiana University Laboratory Animal Resource Center (LARC) 
according to IACUC guidelines and protocols. The resulting offspring were kept without 
tetracycline to induce endothelial HIV-Nef. Of note, we could only use female mice, 
because there were extremely low numbers of male transgenic littermates for reasons 
unknown. 
7 Physiological Assessment of Lungs in Nef Transgenic Mice 
 Blood oxygenation levels were measured in alert animals using MouseOx Plus 
neck sensor (Starr Life Sciences, Oakmont, PA). Lung inspiratory capacity was measured 
with the flexiVent system (Scireq) as previously described [142]. 
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8 Reagents  
Anti-Nef SN20 antibody, anti-Nef SN43 antibody [162], anti-Nef 3D12 (Abcam), 
anti-Nef rabbit polyclonal serum and anti-Nef EH1 antibodies (AIDS reagent repository) 
were all used to detect HIV-Nef. The anti-EMAPII neutralizing monoclonal antibody 
M7/1 was produced and purified, as recently described [158]. Anti-CXCR3 
(Clone:MAB160) was purchased from R&D Systems, Inc. Anti-Nef Elisa was purchased 
from Immunodiagnostic Systems. Recombinant EMAPII was purchased from Sino 
Biological Inc. Alexa Fluor 647-C2-maleimide (A20347) and Alexa Fluor 488-C5-
maleimide (A10254) were purchased from Thermo Fisher Scientific Inc. NHS-EG12-
thiol-acetyl (10852) was purchased from Quanta BioDesign, Ltd. Apologix Caspase 
3/7(Cell Technology, FAM200-2) and the Apo-BrdU apoptosis detection kit 
(Thermofisher, USA, 88-6671-88) were used to stain for apoptotic cells.  
The following reagents were purchased from the vendors listed: Atorvastatin 
(Sigma Aldrich, USA), 4-Hydrotamoxifen (Sigma Aldrich, USA), NSC23766 (Cayman 
Chemical, USA).  Calcein AM, Cell Tracker Deep Red, Dihydroethidium and C12FDG 
were purchased from Thermo Fisher, USA. 
The following reagents were obtained through the NIH AIDS Reagent Program, 
Division of AIDS, NIAID, NIH: Nef-ER #31 Clone from Drs. Scott Walk, Kodi 
Ravichandran, and David Rekosh; Anti-HIV-1 SF2 Nef Monoclonal (EH1) from Dr. 
James Hoxie; Cat #2949; Anti-HIV-1 Nef Polyclonal from Dr. Ronald Swanstrom; 
pcDNA3.1SF2Nef (Cat #11431) from Dr. J. Victor Garcia; 1SF2NefF195R (Cat#11430) 
from Dr. J. Victor Garcia and pNL4-3 from Dr. Malcolm Martin. 
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UV-NBS Antibody Conjugation and Indole-EG12-Thiol Synthesis were 
performed as previously described [163, 164]. Briefly, Indole-EG12-Thiol was 
synthesized by incubating excess tryptamine hydrochloride with NHS-EG12-thiol-acetyl 
in PBS for 2 hours at room temperature. The thiol group was deacetylated by incubating 
with 0.5M hydroxylamine and 25 mM EDTA for 2h at room temperature. The resulting 
reaction mixture was purified via RP-HPLC on a Zorbax C18 column and mass verified 
using ESI-MS. The purity was confirmed using RP-HPLC on an analytical Zorbax C18 
column (>95%), and the yield was 80%. For the UV-NBS conjugation, the antibody was 
first buffer-exchanged using 10 kDa molecular weight spin concentrators in PBS pH7.4 
with no stabilizers. Purified anti-Nef antibodies (SN20, 3D12, and EH1) were then 
incubated with 300 µM of Indole-EG12-Thiol for 15 min at room temperature and were 
UV crosslinked in a Spectroline Select Series crosslinker (254 nm) for a total of 1.1 J/cm2 
energy exposure. Excess thiol linker was removed via a molecular weight cutoff filter. 
The NBS site-specific thiolated antibody was then incubated with either Alexa Fluor 647 
C2 Maleimide or Alexa Fluor 488 C5 Maleimide (100 µM) for 3 hrs at room temperature, 
protected from light. Excess fluorophore was removed via a molecular weight cutoff 
filter, resulting in site-specific fluorescent labeling of the antibody at the conserved 
antibody NBS. Conjugation and labeling efficiency were confirmed via absorbance 
spectrum with a resulting conjugation yield of 1 fluorophore per antibody.   
9 Adhesion Assay (Static Conditions) 
HIV-Nef expressing SupT1 T cells were labeled with Calcein AM dye and 
allowed to adhere to HCAEC monolayer labelled with Cell Tracker Deep Red for one 
hour. After washing away non-adhered cells, the remaining T cells and HCAEC were 
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harvested with trypsinization. The cellular mix was analyzed using flow cytometry and 
adhesion defined as the percentage of green T cells compared to red HCAECs. 
10 Microfluidic Device Fabrication and Seeding 
For the flow studies we used a microfluidic device with channel dimensions of 
1000 μm x 100 μm (width x height), using standard soft lithography techniques as we 
described previously [165]. Briefly, first the device master was fabricated using SU-8 
2075 (MicroChem Corp., USA) photoresist and standard photolithography, and then the 
microfluidic device was fabricated using this master and casting PDMS (Corning, USA) 
at a 10:1 base to curing agent ratio. Prior to cell seeding, the microfluidic devices were 
coated with fibronectin (50 μg/mL, Sigma-Aldrich, USA) for one hour at room 
temperature. Endothelial cells were trypsinized and resuspended at a density of 2.0 x 107 
cells/mL in EMG2 (Lonza, Switzerland). Approximately 20 μL of the cell suspension 
was flowed through the device and kept under static conditions in EGM+ for 24 hours to 
allow for cell attachment.  
11 T-Cell Adhesion Assay (Flow conditions) 
Before the perfusion assay T-cells (either Nef-ER or SupT1) were incubated with 
1μM 4-hydrotamoxifen at 37°C for 6-12 hours.  In drug testing experiments, cells were 
incubated with 10μM Atorvastatin for 12 hours. After incubation, t-lymphoblasts were 
resuspended at 2.0 x 106 cells/mL and stained with 5µmol/l Calcein AM for 30 minutes at 
37°C. After incubation, T cells were spun down and the Calcein AM was removed and 
were again resuspended at a density of 2.0 x 106 cells/mL. The endothelial cell seeded 
microfluidic device was place in a microscopy incubation chamber (Zeiss, Germany) at 
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37°C with 5% CO2.  Suspended T cells were then perfused using a syringe pump (Pump 
11 Elite Series, Harvard Apparatus) at a rate of 18 μL/hr (giving a wall shear stress of 3 
dyne/cm2) for 25 minutes. Fluorescence and brightfield timelapse imaging (6 
images/min) was performed during perfusion using a fluorescence microscope (Zeiss Z1, 
Hamatsu C11440 digital camera). Images were exported and analysis was performed 
using NIH ImageJ software. The number of attached cells in the field of view (FOV) was 
counted and the attachment to the entire device was calculated by multiplying the 
attached cells in the FOV by the length of the channel divided by the length of the FOV. 
Percent cell attachment was calculated by dividing the total number of attached cells by 
the total number of cells perfused over the 25 minutes of perfusion. 
12 Cytoplasmic Transfer 
Control SupT1 T cells or Nef expressing SupT1 T cells were labelled with 
cytoplasmic dye Cell Tracker Deep Red and co-cultured with Calcein AM labeled 
HCAECs. After six hours, T cells were removed with 5x washes with PBS. HCAECs 
were then analyzed using flow cytometry and cytoplasmic transfer quantified as the 
percent of HCAECs that were double positive for Cell Tracker Deep Red and Calcein 
AM. Confocal images were taken using Leica SP8 Resonant-scanning 
confocal/multiphoton microscope. 
13 Co-culture Conditions 
HMVEC were grown to 70-80% confluence in EGM-2MV. T cells were co-
cultured, along with HMVEC, in a 2:1 ratio overnight. The T cells were washed away 3 
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times with PBS. HMVEC were harvested with trypsinization, followed by neutralization 
with serum-containing media.  
14 HIV Viral Infection 
Frozen viral supernatants were obtained from HEK293T cells transfected with 
pNL4-3 and pNL4-3ΔNef plasmids. The supernatants were used to infect Jurkat T cells. 
20ng/ml of virus was used to infect 500,000 cells, and HIV+ was determined with p24 
ELISA of supernatant. 
15 Bronchoalveolar Lavage Samples 
Acellular bronchoalveolar lavage (BAL) fluid and cells derived from BAL were 
obtained from 18 individuals. 14 HIV-1+ patients were on ART for a minimum of three 
years. One patient was HIV2+ and three were HIV uninfected volunteers. Acellular BAL 
fluid was centrifuged at 10,000g for 30 min, followed by 400,000g for 1 h, to isolate 
extracellular vesicles. Anti-Nef Elisa (Immuonodiagnostic Systems, USA) and western 
blot were used to quantify and detect HIV-Nef protein, respectively. Non detectable virus 
was extended to newer (more sensitive) assessments with <20 copies per ml blood. 
Primary alveolar macrophages were isolated from BAL fluid and allowed to adhere to 
plastic for 2h in RPMI+10% FBS. The non-adhered cells were washed away and the 
adhered alveolar macrophages were cultured overnight in the same medium prior to the 
addition of extracellular vesicles. 
Bronchoalveolar Lavage Fluid was collected from the lung of WT and Nef transgenic 
mice using 0.8ml PBS. The BALF was then centrifuged at 600g to remove cell pellet. 
The RBC were lysed using RBS lysis buffer and the remaining cells counted using a 
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hematocytometer. Protein content in BALF was quantified using Pierce BCA kit (Thermo 
Fisher, USA). 
16 Isolation and Characterization of Extracellular Vesicles from Nef-expressing 
Cells 
Extracellular vesicles were isolated from culture supernatants obtained from 
control and Nef-ER-expressing SupT1 cells and HEK293T cells transfected with either 
empty plasmid, Nef-expressing plasmid, or Nef F195R mutant. For isolation of EV, the 
cells were maintained in exosome-free FBS-containing media. Briefly, the culture 
supernatants were centrifuged for 10 min at 2000 g, followed by filtration through a 0.22 
μm syringe filter (Merck Millipore, USA) to remove cell debris. The supernatants were 
centrifuged at 100,000g for 70 min to isolate EV. The EV obtained were washed once 
with phosphate buffered saline (PBS) and re-suspended in PBS for use in further 
experiments. To estimate the amount of protein carried by the EV, lysis was done in a 1:1 
suspension of EV and RIPA buffer. Bicinchoninic assay (BCA) was performed on the 
lysate and the total protein was calculated. Furthermore, the number and size of the 
extracellular vesicles released by the cells was assessed by NanoSight (Malvern, UK), 
which captures and analyses videos to determine vesicular particle size distribution and 
particle counts. For this, 10 μg of EV were fixed in 4% paraformaldehyde for 15 min at 
room temperature, followed by ultracentrifugation at 100,000g for 70 min. The EV were 
then suspended in 200 μl PBS and appropriately diluted for NanoSight analysis. The 
number of particles per μg of EV protein was also estimated. 3ug of EV (based on protein 
concentration) were added per ml media to test the effects of EV on endothelial cells. 
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17 Fluorescence-activated Cell Sorting  
FACS was performed as previously described [20]. BAL-derived cells were fixed 
in 1% PFA for 15 min at room temperature. Cells were washed with PBS prior to the 
addition of 2 μg anti-EMAPII M7/1-AF488, 5 μl CD45-AF700 (Clone 2D1, BioLegend), 
2.5 μl CD3-BV510 (clone OKT3, BioLegend), 5 μl CD4-PE/Cy7 (Clone RPA T4, 
BioLegend), 2.5 μl CD11b-BV711 (Clone ICRF44, BioLegend), 2.5 μl CD206-BV421 
(Clone 15-2, BioLegend), 5 μl CD8-PercP/Cy5.5 (Clone HIT8a, BioLegend), and 2.5 μl 
HLA-DR-BV 650 (Clone L243, BioLegend) per 1x106 cells. The cells were incubated for 
45 min at room temperature and washed with PBS. Next, the cells were permeabilized 
using the FoxP3 intracellular staining kit (00-5523-00, eBioscience). 1 μl of UV-NBS 
AF-647 conjugated anti-Nef EH1 antibody, 1 μl of UV-NBS conjugated anti-Nef SN20 
antibody, 1 ul of UV-NBS AF-647 conjugated anti-Nef 3D12, and 2 μl of p24-PE (clone 
KC57, Beckman Coulter, Inc.) was added to 1 X 106 cells for 1 hour at room temperature. 
Similar to our previous publication [20]. Cells from HIV negative individuals were used 
to draw the gates for HIV-Nef protein detection in HIV positive patients since HIV 
negative individuals have no HIV-Nef protein. Cells were acquired on BDFortessa and 
data analyzed on FlowJo V10.  
For detecting surface expression of EMAPII in HMVECs, the cells were fixed in 
1% paraformaldehyde for 15 min and stained with 2 μg anti-EMAPII M7/1 in 50 μl 
FACS staining buffer for 45 min at room temperature and washed with PBS. Anti-rat 
AF488 (Life Technologies Corporation) was used as a secondary antibody to detect 
surface EMAPII.  
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HCAEC were stained for VCAM (Clone: STA), ICAM-1(Clone: HA58), P-
Selectin (Clone: AK4) and E-Selectin (Clone: HCD62E) after O/N exposure to HIV-Nef 
containing EV or control EV.The cells were acquired on BD FACSCalibur and data 
analyzed on FlowJo V10. 
Surface EMAPII and apoptosis via cleaved caspase 3 protein was measured as 
previously described [166] . Lung tissue from Nef Transgenic mice or their WT 
littermates were digested with 0.25% collagenase Type I (Stem Cell Technologies, 
Canada) 60 min at 37oC. Homogenates were stained with CD31-APC (Biolegend: 
#102409) /CD326-PerCP-Cy5.5 (118219)/CD45-PE (BD: 561087)/EMAPII antibody 
mixture, or permeabilized (FoxP3 staining kit, eBioscience, San Diego, CA) for FITC-
cleaved caspase 3 mab staining (R&D Systems IC835G025). The cells were acquired on 
BD Fortessa and data analyzed on FlowJo V10. 
18 HIV-Nef Transgenic Expression, Stereology, and Volume-Related Stereology for 
Calculation of the Total Number of Alveoli 
HIV-Nef protein was induced in endothelial Nef transgenic (VE-Cadherin-Nef) mice for 
3 months and the mice were euthanized. After perfusion of the pulmonary artery, the 
lungs were fixed by airway instillation using 4.5% paraformaldehyde. Lung volume was 
assessed by water-displacement method. The lungs were embedded in 3% agar and cut 
into commensurate parallel slices (3 mm each), then dehydrated and embedded in 
paraffin. After staining 3-mm sections with resorcin/fuchsin and nuclear fast red 
(Weigert’s elastin staining), measurement of the number of alveoli was performed on 2 
alternate sections 3-mm thick, with a 3-mm distance from each other, which were placed 
adjacent on the same slide and examined using a light microscope (Leica) equipped with 
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newCast software for stereology (Visiopharm). The physical dissector method was used 
for counting, as previously described [167]. Respective counts were related to the right-
lung volume. 
19 Atorvastatin Gavage Feeding 
C3H mice with transgenic expression of HIV-Nef under Tet promoter were 
crossed with FVB mice expressing Tet Transactivator under VE-Cadherin promoter.The 
resulting Nef-VE Cadherin double transgenic animals were gavage fed 5mg/kg 
Atorvastatin [168] daily for three weeks according to IACUC guidelines. 
20 Aortic Ring Dilation 
Mice from each group were anesthetized by isoflurane and sacrificed by 
decapitation. The aortic arch was isolated from the connective tissues and cut into 2.5 
mm rings in a Ca2+ and Mg2+-free phosphate buffered saline solution. The rings were then 
hung between two wires of the myograph placed in a tissue bath containing the Krebs 
solution of the following composition: 131.5 mMol/L NaCl, 5 mMol/L KCl, 2.5 mMol/L 
CaCl2, 1.2 mMol/L NaH2PO4, 1.2 mMol/L MgCl2, 25 mMol/L NaHCO3, and 10 mMol/L 
glucose, that was saturated with a gas mixture of 95% O2 and 5% CO2; pH 7.4, 37 ˚C. 
The rings were preloaded to 0.4-0.6 g and preconstricted by 10 µMol/L phenylephrine. 
The force of 70 mM KCl-induced contractions was regularly assessed to monitor the 
“health” of the aortic ring during the experiments. All of the experiments were performed 
in the presence of 10 µMol/L indomethacin to avoid the contribution of endogenous 
endothelial vasoconstrictive prostanoids and the SNAP (S-Nitroso-N-acetyl-DL-
penicillamine), a NO donor, was used to be a positive control.  
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21 Inspiratory Capacity Measurements 
Inspiratory Capacity measurements were performed with the flexiVent system 
(Scireq, Canada). Mice were anesthetized with inhaled isoflurane in oxygen and 
orotracheally intubated with a 20-gauge intravenous cannula under direct vision. A good 
seal was confirmed by stable airway pressure during a sustained inflation. Isoflurane 
anesthesia was maintained throughout the measurements, and the mice were 
hyperventilated to eliminate spontaneous ventilation. Starting at FRC, the flexiVent was 
programmed to deliver 7 inspiratory volume steps, for a total volume of 1 ml, followed 
by 7 expiratory steps, pausing at each step for at least 1 second. Inspiratory capacity was 
directly measured by deep inflation maneuver or estimated from minimum of three 
pressure volume loops. 
22 Immunohistochemistry 
Tissue Specimens/Processing: The lung samples were collected and placed in 
10% NBF for fixation. The tissues were processed, embedded, microtomed, and stained 
for both H&E and Van Gieson’s Elastin Stain.  
Whole Slide Digital Imaging: The slides were scanned using the Aperio 
ScanScope CS system (360 Park Center Drive Vista, CA 92081). All images were 
scanned at 20x. The digital whole images were housed and stored in the Aperio Spectrum 
software platform. 
Automatic Image Quantitation: Computer-assisted morphometric analysis of 
digital images was carried out using the Aperio software of the Aperio Imaging system. 
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The specific positive pixel algorithm was used for evaluating the smooth muscle in the 
small arterioles. The size that was analyzed was 30 microns to 75 microns in diameter. 
Whole Slide Digital Imaging: The Aperio whole slide digital imaging system was 
used for imaging. The Aperio ScanScope CS system was used (360 Park Center Drive 
Vista, CA 92081). The system imaged all slides at 20x. The scan time ranged from 1.5 
minutes to a maximum of 2.25 minutes. The whole images were housed and stored in the 
Spectrum software system and images were captured from the whole slides. 
Automatic Image Quantitation: Computer-assisted morphometric analysis of 
digital images was carried out using the Aperio software of the Aperio Imaging system. 
The positive pixel algorithm was used for imaging the Van Gieson elastic slides.  
The Positive Pixel Count algorithm was used to quantify the amount of a specific 
stain present in a scanned slide image.  
To quantify the lungs, we selected three small arterioles per slide. The size 
measured was between 30 microns and 75 microns. Some slides only had 2 small 
arterioles on the cross-section of the lung. The individual sections were averaged for each 
mouse. In order to only capture the smooth muscle layer around the arteriole, a line was 
drawn around the outer edge of the smooth muscle layer of the arteriole and the lumen of 
the arteriole was removed. 
23 Statistical Analysis 
Samples were de-identified and difference between groups analyzed using 
Student T-test with Welch’s correction, one-way ANOVA with Tukey post-hoc multiple 
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comparison and Mann-Whitney non-parametric tests as indicated. Spearman non-
parametric analysis was used to determine correlation. 
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III Results 
1 HIV-Nef protein persists in the lungs of aviremic HIV patients and induces 
pulmonary endothelial cell damage in an EMAPII dependent fashion. 
1.1 HIV-Nef protein persists in the lungs of HIV patients on ART  
In order to establish HIV-Nef protein persistence and distribution in lungs of HIV 
patients on ART, we analyzed cells and acellular fluid from bronchoalveolar lavage 
(BAL) of a well-characterized cohort (Table 1). We first stained BAL-derived cells for 
intracellular HIV-Nef using 3 different anti-Nef monoclonal antibodies directed against 3 
unique HIV-Nef epitopes (mAb: EH1, 3D12, and SN20; Fig.5) to address the high 
mutation rate of HIV proteins. We also utilized a novel UV-NBS ab labeling method 
(Fig.6 and 7) to enhance sensitivity. In our patient cohort, we detected HIV-Nef protein 
persistence in at last 2% of BAL cells in 9 out of 15 HIV-positive patients on ART 
(Fig.2, Fig.8 and Table 1). Using markers for alveolar macrophage and lymphocytes, we 
found that HIV-Nef+ cells were distributed throughout alveolar macrophages, CD4 T 
cells, and CD8 T cells (Fig.3), which is consistent with our previous findings that HIV-
Nef protein is widespread in blood cells [41]. In none of the examined samples was the 
HIV virus detectable based on staining for the HIV protein p24 (data not shown) or deep 
sequencing for HIV viral sequences (RNA and DNA) of BAL (data not shown). In 
concert with recent findings that HIV-Nef persists in plasma EVs of ART patients, we 
demonstrated Nef persistence in BAL-derived EVs (Fig.1, 4 and Table 1). This shows 
HIV-Nef protein is widely distributed in the lungs of HIV-patients even in the absence of 
detectable HIV protein and suggest that this persistence corresponds to a detrimental 
effect in patient lungs by promoting a pro-apoptotic environment.   
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Figure 1: HIV-Nef protein persists in lungs of HIV patients on ART. HIV-Nef protein 
was detected using ELISA in extracellular vesicles isolated from HIV patients on anti-
retroviral therapy for at least three years.   
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Figure 2: HIV-Nef protein persists in lung derived cells of HIV patients on ART. HIV-
Nef protein was detected intracellularly in bronchoalveolar lavage (BAL)-derived cells 
using flow cytometry (% Nef positive cells). 
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Figure 3: HIV-Nef protein persists in multiple compartments of lungs of HIV patients on 
ART. HIV-Nef protein was detected intracellularly in bronchoalveolar lavage (BAL)-
derived cells using flow cytometry (% Nef positive cells).  
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Figure 4: Western blot analysis of extracellular vesicles isolated from acellular BAL fluid 
(Upper: Anti-Nef SN43ab) and (Lower: Anti-Nef Polyclonal Rb Serum). 
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Figure 5: Schematic of the antibody cocktail used for intracellular Nef detection using 
conserved domains. 
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Figure 6: Scheme demonstrating the method of UV-NBS conjugation through a site-
specific non-native thiol. 
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Figure 7: Spectrums of the antibodies before and after demonstrating fluorescent 
labelling of the antibody. 
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Figure 8: Representative flow cytometry scatter plot showing HIV-Nef staining in BAL-
derived cells from control HIV-Patient 8 (Black dots) and HIV+ Patient 10 (Red dots, 
Nef+ = 9.86%). 
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Table 1: Bronchoalveolar Lavage fluid from 18 patients were analyzed for HIV-Nef 
persistence and EMAPII surface expression. CD4 cell counts and smoking status of each 
individual is also characterized.   
Pt. 
ID 
Nef+ 
BAL 
cells 
(%) 
[Nef] 
in EV 
(ng/ml) 
EMAP
II + 
BAL 
cells 
(%) 
CD4 
cell 
count 
Smoking 
status 
8 0.63 N/A 1.41 HIV- Yes 
10 9.86 0 6.62 709 Former 
16 3.13 0 6.06 707 Former 
18 2.22 1.5 2.99 688 Former 
19 6.75 6.5 12.3 N/A Former 
20 8.24 1.7 0.55 985 No 
21 2.6 0 0.54 904 No 
22 0.15 3.8 0.03 771 Yes 
23 2.31 0 0.02 158 Yes 
24 0.03 0 0.00 1305 Yes 
25 2.83 8.5 3.23 495 No 
26 0.27 6.5 0.12 737 Yes 
27 0.5 N/A 0.1 HIV- Yes 
28 18.4 4.7 0.25 966 No 
29 0.2 0.5 0.06 158 Yes 
30 0.21 4.3 0.1 231 Former 
31 0.98 N/A 0 HIV- Yes 
32 0.1 1.6 0.03 332 Former 
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1.2 BAL fluid induced endothelial cell apoptosis in HIV+ patients is Nef-dependent 
and mediated by EMAPII 
We followed up our observation of Nef persistence in BAL by studying the role 
of EV in HIV patient’s lung microenvironment. BAL fluid from four HIV- patients and 8 
HIV+ patients were added to HMVEC in a 1:10 dilution in EGM2MV media and 
cultured for 16h. BAL from HIV+ patients significantly upregulated early apoptosis 
marker, Annexin V in HMVEC (Fig.9). To determine whether HIV BAL induced 
HMVEC apoptosis was dependent on Nef persistence, BAL fluid from 4 HIV-, 4 HIV+ 
Nef+ and 4 HIV+ Nef- were added to HMVEC at 1:10 dilution.  Interestingly, only the 
persistent BAL was capable of induced HMVEC apoptosis measured using TUNEL 
labeling as a late stage marker for apoptosis (Fig.10). These findings were confirmed 
with JC-1 staining to measure mitochondrial depolarization. JC-1 (Fig.11). The dye 
aggregates in the negatively polarized mitochondria and fluoresces red (590nm)   but 
fluoresces green (520nm) in the cytoplasm. Therefore, a drop in red/green ratio indicated 
mitochondrial depolarization which is an early marker for apoptosis. Using this assay, 
Nef-dependent HIV BAL induced HMVEC apoptosis was confirmed.  The fourth 
indicator for pro-apoptotic signaling was active caspase 3 signaling in HMVEC treated 
with BAL from 6 HIV-. 6 HIV+Nef+ and 6 HIV-Nef- patients (Fig.12). Interestingly, in 
all four assays, HIV BAL induced HMVEC apoptosis was abrogated when 10μg/ml of α-
EMAPII neutralizing monoclonal antibody - M7/1 suggesting that BAL induced HMVEC 
apoptosis was mediated by the pro-apoptotic protein EMAPII.  
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Figure 9: Addition of 50μl of acellular BAL fluid from HIV- and HIV+ patients for 16h 
to 450μl EGM2MV induces surface expression of early apoptosis marker –as detected 
using Annexin V FITC staining. Addition of 10μg/ml α-EMAPII neutralizing antibody, 
M7/1 abrogated HIV BAL induced HMVEC apoptosis.  
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Figure 10: Addition of 50μl of acellular BAL fluid from HIV-, HIV+ Nef+ and HIV+ 
Nef- patients for 16h to 450μl EGM2MV induces apoptosis –as detected using TUNEL 
staining to identify DNA fragmentation. Addition of 10μg/ml α-EMAPII neutralizing 
antibody, M7/1 abrogated HIV BAL induced HMVEC apoptosis.  
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Figure 11: Addition of 10μl of acellular BAL fluid from HIV-, HIV+ Nef+ and HIV+ 
Nef- patients for 16h to 90μl EGM2MV induces apoptosis – as detected using JC1 
staining to quantify mitochondrial depolarization, an early marker of cellular apoptosis 
indicated by a drop in aggregate/monomer ratio.  Addition of 10μg/ml α-EMAPII 
neutralizing antibody, M7/1 abrogated HIV BAL induced HMVEC apoptosis. 
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Figure 12: Addition of 10μl of acellular BAL fluid from HIV-, HIV+ Nef+ and HIV+ 
Nef- patients for 16h to 90μl EGM2MV induces apoptosis –as detected QVD-FVB 
peptide to measure active caspase 3 signaling.  Addition of 10μg/ml α-EMAPII 
neutralizing antibody, M7/1 abrogated HIV BAL induced HMVEC apoptosis. 
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1.3 Nef containing Extracellular Vesicles mediates BAL fluid induced HMVEC 
apoptosis in an EMAPII dependent fashion. 
Since we were able to isolate the pro-apoptotic HIV viral protein from the 
extracellular vesicle fraction of HIV patient BAL fluid, we tested if the extracellular 
vesicle fraction could induce HMVEC apoptosis in a Nef dependent fashion. We isolated 
EV from 50μl of BAL from 6 HIV-, 17 HIV+ Nef+ and 19 HIV+Nef- patients 
(classification based on Nef ELISA) and resuspended in 100µl EGM2MV. After 16h 
treatment, only the HIV+ Nef+ EV induced HMVEC apoptosis as measured through 
mitochondrial depolarization with JC-1 staining (Fig.13) and active caspase 3 signaling 
(Fig.14). Interestingly, this extracellular vesicle induced HMVEC apoptosis could be 
completely blocked using 10μg/ml α-EMAPII neutralizing monoclonal antibody, M7/1.  
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Figure 13: Addition of extracellular vesicles isolated from 50μl of acellular BAL fluid 
from HIV-, HIV+ Nef+ and HIV+ Nef- patients for 16h to 100μl EGM2MV induces 
apoptosis –as detected using JC1 staining to quantify mitochondrial depolarization, an 
early marker of cellular apoptosis indicated by a drop in aggregate/monomer ratio.  
Addition of 10μg/ml α-EMAPII neutralizing antibody, M7/1 abrogated HIV BAL 
induced HMVEC apoptosis.  
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Figure 14: Addition of extracellular vesicles from 50μl of acellular BAL fluid from HIV-, 
HIV+ Nef+ and HIV+ Nef- patients for 16h to 100μl EGM2MV induces apoptosis –as 
detected QVD-FVB peptide to measure active caspase 3 signaling. Addition of 10μg/ml 
α-EMAPII neutralizing antibody, M7/1 abrogated HIV BAL induced HMVEC apoptosis. 
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1.4 HIV-Nef mediates its own transfer into extracellular vesicles 
HIV-Nef was suggested to exert its function through insertion into and transport 
through EV [43-45, 47, 49, 169, 170]. Here, we investigated how HIV-Nef impacts EV 
formation and mediates its own incorporation into EV. When HIV-Nef was induced in a 
4-hydro-tamoxifen (4-HT)-inducible expression system using a SupT1 T-cell cell line, a 
strong increase in EV secretion was observed (Fig.15). Likewise, HIV-Nef transfection 
into HEK 293T cells resulted in an increase in the number of secreted EV (Fig.16). These 
HIV-Nef induced increase in EV secretion was abrogated when HEK 293T were 
transfected with HIV-Nef F195R, a mutant incapable of PAK2 activation [171, 172]. 
This suggests that HIV-Nef modifies EV packaging and secretion contingent on PAK2 
activation, a pathway implicated in exocyst complex mediated vesicular transport and 
exocytosis. Similarly, PAK2 inhibition with 5µM FRAX 597 reversed HIV-Nef induced 
increase in EV release (Fig.17 & 18). We found that PAK2 activation is also required for 
the incorporation of HIV-Nef into EV (Fig.19). Pak2 is also known as Rac1 activated 
kinase and nef-Rac1 interaction is usually required for Pak2 activation. In support of this, 
Rac1 silencing using siRNA was able to block Nef-induced increase in EV release 
(Fig.20) Interestingly, HIV-Nef containing EV from transfected cells induces the release 
of pro-inflammatory cytokines like TNFα, IL-6, MCP-1, IP-10 and RANTES (Table 2) 
when added to freshly isolated primary human alveolar macrophages. Our data suggest 
that HIV-Nef persistence in the lung involves packaging of HIV-Nef into EV and that 
this EV are capable of promoting pathological activities in vitro.   
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Figure 15: NanoSight based size and number analysis of extracellular vesicles secreted 
from Nef-ER expressing SupT1 T cells.  
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Figure 16: Analysis of HIV-Nef protein expression in extracellular vesicle. NanoSight 
based size and number analysis of extracellular vesicles secreted from HEK 293T 
transfected with either empty vector (mock), wt Nef (Nef) or Nef mutant incapable of 
Pak2 activation (Nef F195R).  
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Figure 17: Analysis of HIV-Nef protein expression in extracellular vesicle. NanoSight 
based size and number analysis of extracellular vesicles secreted from Nef-ER (nef) 
expressing SupT1 T cells (mock) in the presence/ absence of Pak2 inhibitor FRAX 597. 
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Figure 18: NanoSight based number analysis of extracellular vesicles secreted from HEK 
293T transfected with Nef cDNA in the presence/absence of Pak2 inhibitor FRAX 597. 
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Figure 19: Representative western blot of EV isolated from HEK 293T cells transfected 
with empty vector (mock), wt Nef, or Nef mutant incapable of activating PAK2 (Nef 
F195R). CD63 antibody was used to show EV in all lanes. 
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Figure 20: NanoSight based number analysis of extracellular vesicles secreted from HEK 
293T cells transfected with Nef cDNA along with Rac1 silencing. 
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Table 2: The addition of Nef containing EV isolated from transfected HEK 293Ts to 
primary BAL derived alveolar macrophages induced the secretion of pro-inflammatory 
cytokines after 4h measured using BD CBA.  
Treatment 
TNFα 
(pg/ml) 
IL-6 
(pg/ml) 
IP-10 
(pg/ml) 
MCP-1 
(pg/ml) 
RANTES 
(pg/ml) 
Untreated 5.4 8.6 0 78.6 0 
Mock EV 8.6 8.3 0 92.3 1.7 
Nef EV 2015.1 1820.3 33.4 223.3 10.8 
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Table 3: Cytokines concentration in BAL and plasma of HIV patients on ART classified 
by Nef persistence in extracellular vesicles or BAL derived cells. 
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1.5 HIV-Nef Protein induces EMAPII surface expression 
 Based on our previous findings that HIV envelope protein GP 120 induces the 
surface expression and release of EMAPII, a central mediator of emphysema 
development and progression [158, 173, 174]; we raised the question whether the 
persistent intracellular HIV viral protein, HIV-Nef can also cause EMAPII release. 
First, we investigated whether cells found in HIV-Nef containing lung 
microenvironments would be enriched for EMAPII surface expression. Indeed, we 
observed a strong correlation between the percentage of Nef positive (Nef+) cells in the 
BAL and the percentage of EMAPII positive (EMAPII+) cells (Spearman correlation 
coefficient: 0.74; p=0.0006) (Fig.21). 
To show that HIV-Nef expression can independently induce EMAPII trafficking 
to the cell surface membrane, we transfected HEK 293T cells with cDNA to express 
HIV-Nef protein. Compared to mock-transfected HEK 293T cells, SF2 HIV-Nef 
transfected cells showed increased EMAPII surface expression (p < 0.001) (Fig.22). This 
EMAPII upregulation was dependent on PAK2 activation, as the Nef F195R mutant did 
not induce EMAPII surface expression (Fig.22). Likewise, the addition of 5 µM 
FRAX597, a PAK2 inhibitor, abrogated EMAPII surface expression in HIV-Nef 
transfected HEK 293T cells (Fig.23). Similarly, 4-HT activation of Nef-ER expressing 
SupT1 T cells also induced an increase in surface EMAPII expression (Fig.24). 
Next, we analyzed the impact of HIV-Nef protein persistence in the lung on 
EMAPII surface expression in the lung endothelium. We tested the hypothesis that Nef-
containing EV or Nef-expressing T-cells can induce EMAPII expression in HMVECs. 
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The addition of Nef-ER-expressing SupT1 cells (Fig.25) and EV from HIV-Nef-
transfected HEK 293T (Fig.26) significantly induced EMAPII surface expression in 
HMVECs. Again, use of a PAK2 activation incapable mutant (Fig.26) abrogated 
EMAPII surface expression in EV treated HMVECs and pulmonary arterial endothelial 
cells (Fig.27), respectively. 
We and others have reported that HIV-Nef protein can be transferred to 
endothelial cells and that its transfer stresses endothelial cells, which is a precursor for 
the development of vascular lesions [175-177]. Based on these reports, we wanted to 
know whether HIV-Nef in endothelial cells was sufficient to cause EMAPII upregulation 
in vivo. To this end, we crossed HIV-Nef transgenic mice containing the tetracycline-
responsive element with the VE-Cadherin promoter controlled tet-off-transactivator 
mouse line [178]. The resulting offspring were kept for the duration of life without 
tetracycline to induce endothelial HIV-Nef, which led to a statistically significant rise in 
EMAPII surface expressing endothelial cells isolated from the lungs of VE-Cadherin-Nef 
double transgenic vs wild-type littermates (Fig.28). 
These data suggest that HIV-Nef persistence in the ART-treated HIV population 
leads to EMAPII upregulation in vitro and in vivo. 
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Figure 21: BAL-derived cells of 17 patients from INHALD cohort were stained for 
intracellular Nef and surface EMAPII. The percentage of Nef+ and EMAPII+ cells were 
quantified using flow cytometry. Shown is a Spearman correlation between intracellular 
Nef and surface EMAPII expression. 
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Figure 22: EMAPII surface expression was measured in HEK 293T transfected with 
empty vector (mock), wt Nef (wt Nef), or Nef mutant incapable of activating PAK2 (Nef 
F195R).  
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Figure 23: Transfection of HIV-Nef overexpressing plasmid in HEK293T-induced 
EMAPII surface expression, which was blocked using 5uM FRAX597, a PAK2 inhibitor. 
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Figure 24: Nef-ER-expressing SupT1 T cells showed increased EMAPII surface 
expression upon activation with 4-HT.  
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Figure 25: EMAPII surface expression in HMVEC 24 h after the addition of tamoxifen 
(4-HT) activated Nef-expressing SupT1 T cells (Nef-ER) or 4-HT activated control 
SupT1 T cells (SupT1). 
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Figure 26: EMAPII surface expression in HMVEC 24 h after the addition of EV isolated 
from either Nef wildtype (Nef) or Nef-mutant (Nef F195R) transfected HEK 293T 
supernatants. 
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Figure 27: Addition of extracellular vesicles isolated from HEK 293T transfected with 
empty control vector, WT Nef, or Nef F195R, a mutant incapable of PAK2 activation 
induced EMAPII surface expressing in human pulmonary artery endothelial cells. 
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Figure 28: EMAPII surface expression was measured in CD45-/CD326-/CD31+ cells 
isolated from lungs of HIV-Nef transgenic mice and their littermates. The means of each 
group was compared using Student T-test or one-way ANOVA with Tukey post hoc 
comparison. 
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1.6 HIV-Nef Protein induces pulmonary endothelial cell apoptosis in an EMAPII-
dependent fashion  
We have previously shown that HIV-Nef protein can independently mediate its 
transfer from T cells to endothelial cells. We also found HIV-Nef transfer is necessary 
and sufficient to induce endothelial cell ROS production and apoptosis [177]. To address 
the role of EMAPII surface expression in HIV-induced endothelial cell apoptosis, we 
observed a significant increase in HMVEC apoptosis when co-cultured with HIV-NL43-
infected Jurkat T cells (Fig.29) which was abolished in cells treated with anti-EMAPII 
antibodies. Previously, we have shown that HIV induced Human Coronary Artery 
Endothelial Cell apoptosis was HIV-Nef dependent [177]. Supporting this finding, HIV 
induced HMVEC apoptosis was also HIV-Nef dependent. Jurkat cells infected with HIV-
NL4-3 mutant with defective Nef (NL4-3 ΔNef) had no significant upregulation of 
HMVEC apoptosis compared to uninfected Jurkat cells (Fig.29).  
To examine the role of EMAPII in HIV-Nef-induced endothelial apoptosis, we 
analyzed endothelial cell apoptosis in the co-culture model of Nef-ER-expressing SupT1 
cells (Nef-ER) and HMVECs. Co-incubation with 4-hydro-tamoxifen (4-HT) activated 
Nef-ER increased endothelial cell apoptosis as measured by TUNEL staining (p<0.05) 
(Fig.30) and promoted mitochondrial depolarization, an early marker for apoptosis as 
measured by JC-1 staining (p<0.01) (Fig.31). The addition of neutralizing antibodies 
against EMAPII and the EMAPII-receptor (CXCR3) abolished Nef-ER cell-induced 
HMVEC apoptosis (Fig.30) and anti-EMAPII antibodies prevented HMVEC 
mitochondrial depolarization (Fig.31) indicating that EMAPII surface expression plays 
an important role in mediating HIV-Nef induced endothelial apoptosis. Furthermore, 
secreted EMAPII may potentiate HIV-Nef induced endothelial apoptosis since the 
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addition of recombinant EMAPII to a co-culture of Nef-ER SupT1 T cells and 
endothelial cells further enhanced endothelial cell apoptosis (Fig.32).  
Finally, when HIV-Nef positive and HIV-Nef negative EV (Fig.19) were added to 
endothelial cells, only the HIV-Nef containing EV induced dose-dependent (Fig.33) 
apoptosis in HMVECs after 24h but not after 4h (Fig.34). This HIV-Nef EV-induced 
apoptosis was prevented with EMAPII neutralizing antibody treatment (Fig.35). Taken 
together, these data clearly demonstrate that HIV utilizes HIV-Nef-induced and EMAP-
mediated pathways to induce apoptosis in endothelial cells. 
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Figure 29: Apoptosis of HMVEC co-cultured with HIV NL4-3-infected Jurkat T cells 
with/without EMAPII neutralizing antibodies and Jurkat T cells infected with HIV-NL4-
3 with defective Nef- (ΔNef) induced apoptosis, as measured by TUNEL. 
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Figure 30: Co-culture of tamoxifen (4-HT) activated Nef-ER-expressing SupT1 T cells 
(with/without EMAPII and CXCR3 neutralizing antibodies) and 4-HT activated control 
SupT1 T cells induce HMVEC apoptosis as measured by TUNEL staining. 
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Figure 31: Confirmation of apoptosis staining through TUNEL by JC-1 staining, which is 
indicative for mitochondrial function. Note the decreased staining of JC-1 after exposure 
to 4-HT activated Nef-ER SupT1 cells. 
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Figure 32: Co-culture of Nef expressing T cells induced increased endothelial cell 
apoptosis which was comparable to the amount of endothelial cell apoptosis induced by 
control T cells with the addition of 10µg/ml recombinant EMAPII. The addition of Nef 
expressing T cells and recEMAPII induced a synergistic increase in endothelial cell 
apoptosis suggesting that EMAPII primes endothelial cells for Nef induced apoptosis. 
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Figure 33: Apoptosis was measured in HMVEC after the addition of EV from 
supernatant of Mock, WT Nef or Nef F195R (PAK2 activation mutant) transfected 
HEK293T. Dose response of EV addition on Caspase 3 activity in HMVEC at 24hr. 
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Figure 34: Apoptosis was measured in HMVEC after the addition of EV from 
supernatant of Mock, WT Nef or Nef F195R (PAK2 activation mutant) transfected 
HEK293T. Caspase 3 activity was measured at 4hr and 24hr after the addition of 3µg/ml 
EV. 
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Figure 35: Effects on HMVEC apoptosis (determined by staining for active caspase 3) 
after addition of HIV-Nef-containing extracellular vesicles from HEK 293T cells 
transfected with wt HIV-Nef plasmid or HIV- Nef F195R mutant. 
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1.7 Endothelial HIV-Nef expression in transgenic mice induces pulmonary 
pathology  
To test whether Nef transfer to the endothelium is sufficient to cause pulmonary 
pathologies, we analyzed mice in which Nef was specifically expressed in the 
endothelium under control of VE-cadherin promoter. At the age of 4 month, Nef- 
expressing mice did not manifest significant changes in weight comparing to their Nef-
negative WT littermates (data not shown). However, pulse oximetry showed statistically 
significant reduction in blood oxygenation (p = 0.016) in VE-Cadherin-Nef double 
transgenic mice (Fig.36). PFT analysis of 5 month-old animals showed significant 
increase in inspiratory capacity measured using both deep inflation maneuver (grey bars) 
and extrapolated from PV loop (red bars) (Fig.37) indicating lung tissue rarefaction 
[179]. Indeed, stereological analysis demonstrated a decrease in alveoli numbers in HIV-
Nef transgenic animals compared to their Nef-negative WT littermates (Fig.38). 
Importantly, endothelial cells from lungs of Nef-expressing mice manifested higher 
percentage of cleaved caspase 3- positive cells (Fig.39), suggesting a possible role of 
Nef-induced apoptosis in alveolar loss. Interestingly, this effect was abrogated upon two-
time intraperitoneal injection of 10μg/ml EMAPII neutralizing antibody, M7/1.However, 
we failed to observe significant changes in wet/dry lung ratio, WBC or protein infiltration 
in lung (Fig.40). These data highlight the notion that HIV-Nef causes EMAPII mediated 
endothelial apoptosis, followed by lung tissue rarefaction and are in line with our 
previous findings in lungs of EMAPII transgenic mice [142]. 
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Figure 36: Oximetry showed reduced oxygenation in the blood of HIV-Nef transgenic 
mice. 
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Figure 37: Inspiratory capacity was quantified using deep inflation maneuver (grey bars) 
and extrapolated from PV loop (black bars) using Flexivent data analysis. 
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Figure 38: Stereological analysis revealed corresponding reduction in alveoli numbers 
VE-Cad-Nef expressing lungs compared to wildtype (WT) littermates. Representative 
H&E staining of VE-Cadherin Nef Transgenic mice and their WT littermates showing 
alveolar rarefaction characteristic of an emphysema like phenotype. 
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Figure 39: Cleaved caspase-3 staining in CD45-/CD326/CD31+ cells from lungs in Nef 
transgenic mice with sham treatment or after 2x i.p injection of anti-EMAPII neutralizing 
antibody 72h and 24h prior to sacrifice. 
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Figure 40: BAL from Nef transgenic mice and their WT littermates were analyzed for (A) 
number of WBC, (C) protein content using BCA and (D) EMAPII using anti-EMAPII 
ELISA (MyBioSource). (B) Lung edema was quantified using wet/dry weight 
measurements of lung. 
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2 HIV-Nef induces endothelial dysfunction in a Rac1 activation dependent manner: 
Implications for statin treatment to protein HIV-associated cardiovascular diseases  
2.1 PBMC of HIV+ patients on ART are HIV-Nef positive and trigger endothelial 
apoptosis. 
HIV-Nef protein has been shown to persist in the circulation of HIV patients on 
ART with undetectable viral loads both intracellularly [177] and in EV [50]. However, 
the high rate of mutation of the HIV virus makes it challenging to accurately quantify the 
amount of HIV-Nef protein. Here we used a novel approach where three antibodies 
(SN20, EH1 and 3D12) targeting different Nef epitopes were used in concert to detect 
intracellular HIV-Nef protein (Fig.5). Analysis of PBMC from fifteen HIV patients on 
ART and four untreated HIV patients revealed that HIV-Nef protein persisted in 3 out of 
4 treatment-naïve and 9 out of 10 ART-treated HIV patients (Fig.41). Importantly, 
analysis of 13 healthy controls revealed undetectable levels of HIV-Nef supporting the 
specificity of our assays. 
In our previously published work [177], we have shown that HIV-Nef protein is 
necessary and sufficient to cause HIV-induced endothelial cell apoptosis. Since HIV-Nef 
expression in analyzed PBMC was not affected by ART therapy, we wanted to determine 
if HIV-Nef positive PBMC will effectively trigger endothelial apoptosis. Added to 
HCAEC, PBMC from HIV patients induced increased levels of active caspase 3 (Fig.42) 
and changes in the EC mitochondrial membrane potential (Fig.43) when compared to 
control PBMC.  
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Since Nef protein was also identified in extracellular vesicles isolated from 
plasma of treatment naïve HIV patient, HIV+ patients on ART with undetectable viremia 
and HIV+ elite controllers with undetectable viral load in blood [50], we wanted to test if 
the extracellular vesicle compartment would be capable of inducing HCAEC apoptosis. 
Using active caspase 3 signaling (Fig.44) and JC-1 staining to measure mitochondrial 
depolarization (Fig.45), we show that only the EV fraction and not the EV depleted 
plasma fraction is capable of inducing HCAEC apoptosis. In line with our identification 
of Nef protein persistence in both ART treated and untreated patients, EV from both ART 
treated and treatment naive HIV patients induced HCAEC apoptosis.  
Taken together, our data suggests that HIV-Nef persists at a higher frequency in 
PBMC of HIV patients than previously estimated and can cause endothelial cell 
apoptosis. Furthermore, the EV fraction of HIV patient blood is also capable of inducing 
endothelial cell apoptosis. 
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Figure 41: HIV-Nef protein persists in the circulation of HIV patients on ART and 
induces coronary artery endothelial cell apoptosis. Nef protein persists in PBMCs of HIV 
patients in both treatment naïve (n=4, square) and ART (n=10, triangle) as measured 
using FACS. 
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Figure 42: Addition of PBMCs from HIV patients to Human Coronary Artery Endothelial 
Cells (HCAEC) induced endothelial cell apoptosis as measured by Active caspase 3 
levels. 
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Figure 43: Addition of PBMCs from HIV patients to Human Coronary Artery Endothelial 
Cells (HCAEC) induced endothelial cell apoptosis as measured by mitochondrial 
depolarization using JC-1 staining.  
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Figure 44: Addition of extracellular vesicles from 50μl plasma added to 100μl EGM2MV 
and 10μl of either whole plasma or EV depleted plasma to Human Coronary Artery 
Endothelial Cells (HCAEC) induced endothelial cell apoptosis as measured by Active 
caspase 3 levels. 
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Figure 45: Addition of extracellular vesicles from 50μl plasma added to 100μl EGM2MV 
and 10μl of either whole plasma or EV depleted plasma to Human Coronary Artery 
Endothelial Cells (HCAEC) induced endothelial cell apoptosis as measured by 
mitochondrial depolarization using JC-1 staining. 
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2.2 HIV-Nef alters T cell adhesion to endothelial cells 
We next characterized whether HIV-Nef could modulate T cell interaction with 
endothelial cells. Using microscopy, we quantified the amount of calcein AM-stained T 
cells adhered to an endothelial monolayer. SupT1 T cells expressing HIV-Nef showed 
increased adhesion to HCAEC monolayer compared to control T cells (Fig.46). HIV-Nef 
is known to activate the small GTPase Rac 1, a regulator of actin remodeling and T cell 
adhesion [reference]. To elucidate the role of Rac1 in HIV-Nef-mediated adhesion, we 
blocked Rac1 activation using two different strategies; first using a Rac-1 GEF 
interaction inhibitor, NSC23766, and second by using Atorvastatin’s pleiotropic capacity 
to inhibit Rac 1 geranylgeranylation. (Fig.46) shows that both inhibition strategies 
negated the ability of HIV-Nef to increase T cell adhesion to endothelial cells. 
We further confirmed our findings in experiments when adhesion of T cell to 
endothelial monolayer was studied under physiological flow conditions (Fig.47). Similar 
to static conditions, Nef-expressing T cells displayed increased attachment to endothelial 
monolayer compared to control T-cells; this increase was completely suppressed in the 
presence of Atorvastatin. 
Altogether, these data demonstrate that HIV-Nef expression promotes T cell 
adhesion to endothelial cells in a Rac 1-dependent fashion.  
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Figure 46: Compared to control SupT1 T cells (SupT1), Nef expressing T cells (Nef-ER) 
displayed increased adhesion to HCAEC under static conditions in the presence/absence 
of Rac1 inhibitor - NSC23766 or Atorvastatin. 
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Figure 47: Compared to control SupT1 T cells (SupT1), Nef expressing T cells (Nef-ER) 
displayed increased adhesion to HCAEC under static conditions in the presence/absence 
of Atorvastatin. 
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2.3 HIV-Nef facilitates cytoplasmic transfer to endothelial cells 
To further characterize how HIV-Nef affects T cell interaction with endothelial 
cells, we studied cytoplasmic transfer between HIV-Nef expressing T cells and HCAEC. 
Using microscopy, we quantified the amount of Cell Tracker Deep Red Dye transferred 
from T cells to endothelium. 
Fig.48 and Fig.49 show that cytoplasmic dye transfer to endothelial cells 
increased in a fashion dependent on the amount of added T cells; signal was invariably 
higher in monolayers interacting with Nef-expressing T cells when compared to control T 
cells. This HIV-Nef-induced increase of T cell cytoplasmic transfer was attenuated by 
both Rac1 inhibitor and Atorvastatin (Fig.50). To confirm that HIV-Nef mediates its own 
transfer by facilitating cytoplasmic transfer from T cells, we assessed HIV-Nef levels in 
endothelium. As expected, HIV-Nef was detected in endothelium interacting with HIV-
Nef-expressing T cells; Rac 1 inhibitor as well as Pitavastatin and Atorvastatin 
significantly attenuated levels of HIV-Nef transferred to endothelium (Fig.51). 
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Figure 48: SupT1 (Left panels) and Nef-ER T cells (Right panels) were co-cultured with 
HCAEC. Nef protein transfer to HCAEC is identified using anti-Nef EH1 mAB (Top 
panels). Cytoplasmic transfer of Cell Tracker Deep Red Dye from T cells is measured in 
Calcein AM stained endothelial cells (bottom panel).   
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Figure 49: Nef expression enhanced cytoplasmic transfer from T cells to endothelial 
cells. Quantification was done using flow cytometry (A) expressed as percent of coronary 
artery endothelial cells double positive for Calcein AM and Cell Tracker Deep Red dye 
and confocal microscopy (B) followed by determination of no. of red vesicles per 
HCAEC cell using IMARIS imaging software. 
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Figure 50: Nef expression enhanced cytoplasmic transfer from T cells to endothelial cells 
expressed as percent of coronary artery endothelial cells double positive for Calcein AM 
and Cell Tracker Deep Red dye indicating cytoplasmic transfer from T cells. Cells were 
treated with Rac1 inhibitor NSC23766 or Atorvastatin. 
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Figure 51: Nef transfer from Nef expressing T cells to endothelial cells expressed as 
percent of coronary artery endothelial cells containing Nef protein after 24h co-culture. 
Cells were treated with Rac1 inhibitor NSC23766, Pitavastatin or Atorvastatin. 
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2.4 HIV-Nef increase adhesion capacity of endothelial cells 
We wanted to study whether exposure to HIV-Nef can influence the adhesive 
capacity of endothelial cells and enhance adhesion of lymphocytes to the endothelium. 
We found that addition of Nef EV (Fig.52 A-D) and co-culture with Nef-ER T cells 
(Fig.53 A-D) induces upregulation of endothelial adhesion markers - VCAM-1, ICAM, 
E-Selectin and P-Selectin. This HIV-Nef induced upregulation of adhesion markers 
subsequently enhanced adhesion of SupT1 T cells to Nef-EV treated HCAEC (Fig.54). 
Interestingly, Rac1 inhibition with NSC23766 and Pitavastatin was capable of abrogating 
Nef induced endothelial cell activation and subsequently, T cell adhesion to endothelial 
monolayer. Nef EV pretreatment also enhanced adhesion of T cells to both microvascular 
(HMVEC) (Fig.55) and macrovascular pulmonary (Human Pulmonary Artery 
Endothelial Cells) (Fig.56) endothelial cells.  
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Figure 52: Addition of Nef EV to HCAEC upregulates surface expression of endothelial 
adhesion markers. VCAM1 (A), ICAM (B), E-Selectin (C) and P-Selectin (D) expression 
levels in HCAEC treated 24hr with 3µg/ml Nef EV in the presence of 5µmol/l 
NSC23766 (Rac1i) or 100nmol/l Pitavastatin. 
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Figure 53: VCAM1 (A), ICAM (B), E-Selectin (C) and P-Selectin (D) expression levels 
in HCAEC co-cultured with Nef-ER T cells or control SupT1 T cells for 24h in the 
presence of 5µmol/l NSC23766 (Rac1i) or 100nmol/l Pitavastatin. 
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Figure 54: T cell adhesion to HCAEC  pre-treated with 3µg/ml Mock/Nef EV in the 
presence of 5µmol/l NSC23766 (Rac1i) or 100nmol/l Pitavastatin. 
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Figure 55: T cell adhesion to HMVEC pre-treated with 3µg/ml Mock/Nef EV in the 
presence of 5µmol/l NSC23766 (Rac1i) or 100nmol/l Pitavastatin. 
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Figure 56: T cell adhesion to HPAEC pre-treated with 3µg/ml Mock/Nef EV in the 
presence of 5µmol/l NSC23766 (Rac1i) or 100nmol/l Pitavastatin 
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2.5 HIV-Nef activates Rac1-Pak2 signaling to induce NADPH Oxidase complex 
mediated production of Reactive Oxygen Species 
Previously we have shown that HIV-Nef protein is necessary and sufficient to 
induce ROS production that leads to endothelial cell apoptosis. In order to further 
elucidate the underlying molecular mechanisms we analyzed the HIV-Nef induced Rac 1 
activation previously shown to cause NADPH dependent ROS production in cells of the 
monocyte-macrophage lineage [108, 109]. HIV-Nef induced ROS production in 
HCAECs transfected with HIV-Nef expressing plasmid was mediated in a Rac 1-Pak2 
pathway (Fig.57). Furthermore, co-culture of Nef expressing SupT1 T cells (Fig.58) and 
addition of Nef EV (Fig.59) induced HCAEC ROS production which was reversed using 
Rac1 inhibitor NSC23766 as well dominant negative Rac T17N and Rac1 siRNA 
showing strong evidence for Rac1 activation being important for Nef induced endothelial 
stress. Nef EV utilizes the NADPH Oxidase complex for reactive oxygen species 
production since inhibition of the complex using GP91 inhibitory peptide, Gp91ds-tat 
(Fig.60). Similarly, statin treatment was capable of inhibiting Nef mediated ROS 
production in all three models tested. 
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Figure 57: Transfection of HIV-Nef plasmid but not Pak2 activation mutant (Nef F195R) 
induced ROS production in HCAEC. Cells were cultured in the presence/absence of Rac1 
inhibitor NSC23766 or Atorvastatin. 
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Figure 58: Co-culture of HIV-Nef expressing T cells induced ROS production in 
HCAEC. Cells were cultured in the presence/absence of Rac1 inhibitor NSC23766 or 
Atorvastatin. 
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Figure 59: HCAEC ROS production after addition of Nef extracellular vesicles isolated 
from HEK 293T transfected with either mock, Nef cDNA or Nef cDNA plus RacT17N 
dominant negative. Rac1 silencing using siRNA in HCAEC concomitant with 
extracellular vesicle addition also blocked Nef induced ROS production.  
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Figure 60: HCAEC ROS production after addition of Nef extracellular vesicles isolated 
from HEK 293T transfected with either mock or Nef cDNA. HCAEC were treated with 
Rac1 inhibitor-NSC23766, Pitavastatin and NADPH inhibitory peptide GP91ds-tat.  
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2.6 HIV-Nef protein induced endothelial cell apoptosis is dependent on Rac1 
activation 
As an extension to the previous finding that NADPH oxidase dependent ROS 
production plays an important role in Nef mediated endothelial cell apoptosis [177], we 
analyzed the role of Rac1 activation in mediating this effect. Using our co-culture model 
of Nef expressing T cells and HCAEC, we observed that Rac1 inhibition using 5μM 
NSC23766 and statin treatment potently blocked Nef induced HCAEC apoptosis 
measured using TUNEL (Fig.61), active caspase 3 signaling (Fig.62) and JC-1 staining 
(Fig.63). This effect was mediated by ROS production since inhibition of NADPH 
Oxidase complex using gp91 inhibitory peptide reversed this effect.  
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Figure 61: Co-culture of Nef expressing T cells induced HCAEC apoptosis measured 
using TUNEL staining. Co-culture was performed in the presence/absence of Rac1 
inhibitor-NSC23766 and Atorvastatin. 
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Figure 62: Co-culture of Nef expressing T cells induced HCAEC apoptosis measured 
using active caspase 3 signaling. Co-culture was performed in the presence/absence of 
Rac1 inhibitor-NSC23766, Pitavastatin and NADPH oxidase inhibition using Gp91 ds-
tat. 
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Figure 63: Co-culture of Nef expressing T cells induced HCAEC apoptosis measured 
using JC-1 staining to measure mitochondrial depolarization. Co-culture was performed 
in the presence/absence of Rac1 inhibitor-NSC23766, Pitavastatin and NADPH oxidase 
inhibition using Gp91 ds-tat. 
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2.7 Extracellular Vesicles containing Nef protein induces Rac1-Pak2 activation 
dependent endothelial cell apoptosis 
Nef transfer via extracellular vesicles was shown to mediate this effect since 
addition of Nef EV also induced HCAEC apoptosis as measured using active caspase 3 
signaling (Fig.64 and 66) and JC-1 staining (Fig.65). However, extracellular vesicles 
isolated from HEK293T co-transfected with Nef and dominant negative Rac1, RacT17N, 
was incapable of inducing HCAEC apoptosis. Furthermore, Rac1 siRNA treatment 
(Fig.64 and 65) and small molecule wt inhibitor, NSC23766 (Fig.66) were able to 
ameliorate Nef EV induced HCAEC apoptosis. Similarly, Pak2 inhibition with 5μM 
FRAX 597 (Fig.66) was able to prevent Nef induced HCAEC apoptosis. Extracellular 
(vesicles isolated from HEK 293T transfected with Pak2 activation incapable mutant, Nef 
F195R was incapable of inducing HCAEC apoptosis (Fig.67).  Therefore, our data 
suggests that Nef EV uptake by HCAEC is followed by endothelial cell apoptosis. This 
Nef induced endothelial cell apoptosis is dependent on Nef-Rac1-Pak2 signaling axis. 
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Figure 64: Active caspase 3 signaling in HCAEC after addition of Nef extracellular 
vesicles isolated from HEK 293T transfected with either mock, Nef cDNA or Nef cDNA 
plus RacT17N dominant negative. Rac1 silencing using siRNA in HCAEC concomitant 
with extracellular vesicle addition also blocked Nef induced apoptosis.  
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Figure 65: Mitochondrial depolarization quantified using JC-1 staining in HCAEC after 
addition of Nef extracellular vesicles isolated from HEK 293T transfected with either 
mock, Nef cDNA or Nef cDNA plus RacT17N dominant negative. Rac1 silencing using 
siRNA in HCAEC concomitant with extracellular vesicle addition also blocked Nef 
induced apoptosis.  
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Figure 66: Apoptosis measured using active caspase 3 signaling in HCAEC after addition 
of Nef extracellular vesicles isolated from control T cells (SupT1) or Nef expressing T 
cells (Nef-ER). Nef EV induced apoptosis was blocked with Rac1 inhibition- NSC23766, 
Statins (Pitavastatin and Atorvastatin) and Pak2 inhibition using FRAX597.  
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Figure 67: Apoptosis in HCAEC measured using active caspase 3 signaling in HCAEC 
after addition of Nef extracellular vesicles isolated from HEK 293T transfected with 
mock, wt Nef or Nef mutant incapable of Pak2 activation (Nef F195R).  
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2.8 Statin treatment alleviates HIV-Nef induced endothelial cell apoptosis 
Since Nef induced ROS production and apoptosis in HCAEC was dependent on 
Rac1-Pak2 activation, we hypothesized that blocking Rac1 trafficking to the membrane 
with statin treatment could pleiotropically help protect HCAEC from Nef induced stress. 
In this regard, treatment with statin blocks Nef induced ROS production in co-culture 
models of HCAEC (Fig.58). Similarly, statin treatment also blocked Nef EV induced 
HCAEC ROS production (Fig.59). Subsequently, in both the co-culture model and Nef 
EV treatment model, statin treatment were comparably effective to Rac1 inhibition or 
NADPH oxidase complex inhibition in terms of protecting HCAEC from Nef induced 
endothelial cell apoptosis (Fig.61, 62, 63 and 66). These findings suggest potential 
therapeutic benefits of prophylactic prescription of statins to HIV patients on ART to 
prevent cardiovascular disease development.  
Therefore, we demonstrate that HIV-Nef protein utilizes a Rac 1 mediated 
pathway to induce HCAEC apoptosis and that statin therapy can be used to protect 
HCAECs from HIV-Nef induced apoptosis.    
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2.9 Endothelial Nef expression leads to vascular pathologies in transgenic murine 
model 
While HIV infection is limited to CD4 T cell and macrophages, we and others 
have shown that HIV-Nef protein is capable of mediating its own transfer to endothelial 
cells. To address the question whether endothelial presence of HIV-Nef protein is 
sufficient to cause vascular pathologies, we generated mice expressing HIV-Nef under 
control of VE-cadherin promoter. 
To achieve that, transgenic mice expressing HIV-Nef under control of tetracycline 
responsive element were crossed with transgenic mice expressing tetracycline operator 
under control of VE-Cadherin promoter. The resultant double transgenic mice were not 
given tetracycline to ensure constitutive expression of HIV-Nef protein in endothelial 
cells.  
Analysis of cardiac phenotype revealed no apparent changes in heart/body weight 
ratio at 4 month of age; however, at 5 month of age Nef+ mice demonstrated noticeable, 
although not significant decrease in heart mass (data not shown). In concert with in vitro 
data, we observed elevated level of endothelial cell apoptosis in the heart of HIV-Nef 
transgenic mice when compared to Nef- littermates (Fig.68) which could be reduced 
using anti-EMAPII neutralizing antibodies. Ultrasonic examination of Nef transgenic 
mice revealed significantly decreased diameter of left carotid coronary artery in HIV-Nef 
transgenic than in Nef-negative littermates (Fig.69).  
To assess endothelial-specific vascular function in Nef transgenic mice, we 
measured dilation of pre-constricted aortic rings in response to acetylcholine. Aortas from 
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3 month-old HIV-Nef transgenic animals showed dramatically impaired ability to dilate 
in endothelial-dependent manner. Importantly, aortas from Nef transgenic animals treated 
for three weeks with Atorvastatin showed normalized dilation in response to 
acetylcholine (Fig.70). This phenotype of impaired endothelium mediated vasodilatory 
capacity was confirmed in another transgenic mouse model with HIV-Nef expression in 
CD4+ cells (Fig.71). 
Analysis of pulmonary phenotype revealed no apparent changes in wet or dry 
lung to body weight ratio in Nef transgenic mice (Fig.40). Nonetheless, we observed 
increased apoptosis in pulmonary endothelial cells of Nef transgenic animals (Fig.39). 
Histological examination of Masson-3-Chrome and Verhoeff-Van Gieson-stained lung 
sections revealed marked changes in the appearance of small pulmonary arteries (Fig.72). 
In particular, small arteries of HIV-Nef transgenic displayed elevated perivascular 
collagen deposition (Fig.73) and increased vessel thickness (Fig.74). With these changes 
being consistent with the signs of developing pulmonary hypertension, we assessed 
PAT/PET ratio known to have inverted relationship with RVSP. PAT/PET was 
significantly decreased in Nef-transgenic mice compared to Nef-negative littermates 
(Fig.75). 
Taken together, our data strongly suggest that endothelial damage by HIV-Nef is 
sufficient to induce variety of vascular pathologies clinically relevant to those observed in 
HIV patients on ART. 
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Figure 68: Cleaved caspase-3 staining in CD45-/CD326/CD31+ cells from the hearts in 
Nef transgenic mice with sham treatment or after 2x i.p injection of anti-EMAPII 
neutralizing antibody 72h and 24h prior to sacrifice. 
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69: Echocardiography was used to evaluate LCCA diameter in 3mo old Nef 
Transgenic mice and their WT littermates 
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Figure 70: Aortic rings isolated from VE-Cadherin Nef expressing mice were 
preconstricted using phenylephrine. Vasodilation in response to increasing concentrations 
of acetylcholine were used to measure endothelium dependent vasodilation. Nef mice 
treated with 5mg/kg of Atorvastatin daily for 3 weeks show improved aortic vasodilation. 
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Figure 71: Aortic rings isolated from CD4c-Nef expressing mice were preconstricted 
using phenylephrine. Vasodilation in response to increasing concentrations of 
acetylcholine were used to measure endothelium dependent vasodilation 
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Figure 72: HIV-Nef transgenic mice display vascular remodeling of small pulmonary 
artery vessels. (A) Trichrome staining shows increased collagen deposition (B) VVG 
staining was used to measure smooth muscle remodeling in arteries <75μM in diameter 
in lung sections. (C) Evidence of elastin degradation.  
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Figure 73: Increased perivascular collagen deposition in VE-Cadherin nef transgenic 
animals when compared to their WT littermates. Collagen deposition was quantified 
using Masson trichrome staining. 
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Figure 74: Increased vascular remodeling in pulmonary arteries with <75μM diameter in 
lung sections of VE-Cadherin Nef transgenic animals when compared to their WT 
littermates. Vascular remodeling was quantified using Verhoef- Von Gieson Staining. 
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Figure 75: PAT/PET ratio was quantified using echocardiography is 3mo old Nef 
transgenic mice and their WT littermates. 
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2.10 Nef expression induces ECFC senescence 
Endothelial colony forming cells are highly proliferative endothelial cells that 
play an important role in repair of damaged vasculature [180]. Here we addressed the 
effect of HIV viral proteins on endothelial colony forming cells. 
Cord blood derived ECFCs were treated with HIV-Nef containing EVs (Fig.76) 
and HIV-Nef expressing SupT1 T cells (Fig.77). Both intracellular and extracellular 
models of HIV-Nef persistence lead to increased senescence of ECFCs. Premature 
cellular senescence was quantified by calculating the percentage of ECFC which were 
positive of senescence associated β – galactosidase activity. This activity was measured 
using the fluorescent dye C12FDG via flow cytometry. Interestingly, treatment with 
Pitavastatin was able to protect ECFCs from HIV-Nef induced senescence. As previously 
observed [181, 182] , statin treatment was in general beneficial to ECFC since ECFC 
senescence was decreased upon Pitavastatin treatment.  
Our results show that HIV-Nef protein is capable of inducing ECFC senescence 
which in turn could lead to the diminished capacity to repair vascular injury in HIV 
patients.  
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Figure 76: Addition of HIV-Nef containing EV induces senescence over 6 days 
(measured through senescence associated β Galactosidase activity) in ECFC which was 
reversed with Pitavastatin treatment. 
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 77: Co-culture of Nef-ER T cells induces senescence over 6 days (measured 
through senescence associated β Galactosidase activity) in ECFC which was reversed 
with Pitavastatin treatment. 
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III Discussion 
1 HIV-Nef persistence and endothelial cell apoptosis 
In this study, we report for the first time that the virally encoded HIV-Nef protein 
persists in lungs of HIV patients on antiretroviral therapy (ART) in both cells and EV 
using three different techniques – flow cytometry to show intracellular Nef and ELISA 
and western blot to detect Nef persistence in extracellular vesicles. Our discovery 
highlights a likely source of cardiopulmonary vascular pathologies even in aviremic HIV 
patients. 
Earlier, our lab had shown that Nef protein persists intracellularly even in patients 
on anti-retroviral therapy, albeit at very low levels. This could be attributed to two major 
challenges associated with detecting Nef protein in HIV patients on ART. The first 
concern is that since HIV has a high rate of mutation, using one antibody targeting a 
specific epitope leads to a scenario of under-reporting the frequency of Nef persistence. 
The second issue that commercially available ELISAs only work in acellular samples, 
thereby limiting the ability to accurately quantify the amount of protein that is present. 
However, the detection of HIV-Nef protein in patients on ART has the potential to 
become a biomarker for HIV reservoir activity and explain the inability of ART to revert 
the development of HIV associated cardio-pulmonary vascular diseases. Hence we used a 
strict validation approach deploying 3 monoclonal antibodies directed against 3 distinct 
epitopes (SN 20, 3D12, and EH1: see Fig.2 and 5) to meet challenges due to the high 
mutation rate of the HIV virus. We also conjugated our anti-nef abs using a novel UV-
NBS conjugation system to enhance sensitivity and specificity of detection. Using this 
approach, we could demonstrate that HIV-Nef is disseminated equally in treated and 
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untreated (viremic) patients, indicating the significance of HIV-Nef for vascular 
complication in this aviremic HIV population. However, future studies accurately 
quantifying the amount of Nef protein present in HIV patients could be used to test if the 
amount of Nef protein predicts disease progression. 
We also observed that HIV-Nef protein can be found in lung alveolar 
macrophages, CD4+ and CD8+ T cells in addition to BAL derived EV [66, 183]. Given 
that there is no cell type specificity of Nef protein expression and deep RNAsequencing 
did not reveal any HIV transcripts, we believe that the most likely explanation of 
disseminated expression of HIV-Nef in BAL cells is that it is a product of fusion with 
Nef containing EV.  We backed up our ELISA quantification previously used to detect 
HIV-Nef in plasma EV [42] with WB using two different antibodies. In this regard, we 
found nearly half the patients to have Nef in extracellular vesicles in the BAL. Our 
hypothesis of HIV-Nef mediating its transfer through EV is in line with findings showing 
the persistence of HIV-Nef in plasma [42, 45] and our previous discovery of this protein 
in HIV-negative T cells and B cells in the blood [184]. While we do not have any 
aviremic HIV patients in the cohort from which we have BAL samples, Lee et.al [45] 
noted that Nef persists in plasma EV of both viremic and aviremic HIV patients. They 
also show that both groups have similar EV profiles as characterized by an increase in 
EV quantity and changes in miRNA and protein cargo when compared to non-infected 
individuals. 
In the context of EV cargo and its biological significance, we demonstrated 
previously that Nef protein persistence in cells can directly lead to endothelial apoptosis. 
Here we show for the first time that HIV-Nef dissemination through PBMC leads to 
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endothelial cell apoptosis. In fact, PBMC from HIV patients on ART demonstrated 
caspase-3 activation and mitochondrial depolarization in cultivated human coronary 
arterial endothelial cells (Fig.42 and 43). The other fraction in which Nef persists, 
extracellular vesicles, is also capable of inducing endothelial cell apoptosis. These EV 
isolated from HIV patients, both from BAL and plasma were potently capable of 
inducing apoptosis in HMVEC (Fig.13 and 14) and HCAEC (Fig.43 and 44) 
respectively. While we only observed a moderate increase in apoptosis when HCAEC 
were cultured with whole plasma and even less with EV depleted plasma (Fig.44 and 
45), a 1:10 dilution of BAL fluid was sufficient to induce potent HMVEC apoptosis in 
the HIV patients who were found to have Nef persistence. While HIV patients without 
detectable Nef had less ability to induce endothelial apoptosis. Therefore, our ability to 
quantify Nef in EV isolated from BAL fluid to classify patients into Nef+ and Nef-
(Fig.1) is of importance as it can be used to stratify patients. We did not have sufficient 
plasma to classify HIV patients into Nef+ and Nef- by analyzing EV isolated from 
plasma. 
HIV-Nef is known to have the ability to interact with vesicular trafficking 
proteins and regulate EV secretion [185]. Similar to previous studies in plasma [44], we 
could not distinguish between micro-particles and exosomes and hence decided to use the 
term extracellular vesicles. To the best of our knowledge; this is the first report 
demonstrating Nef in EV isolated from HIV-infected patient's BAL fluid. This EV could 
be from latently HIV infected T cells and macrophages from HIV reservoirs in the 
lymphatic system as Nef containing EV were shown to be CD45+ [42]. Another possible 
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cellular source for Nef containing EV could be the liver based on miRNA and effector 
protein profiling of Nef containing EV isolated from plasma [47].  
Furthermore, HIV-Nef persistence in the lung of patients corresponds to the 
increased presence of pro-inflammatory chemokines in the lung milieu (Table 1 and 2). 
Although not significant given the relatively small number of patients analyzed, there 
was a trend towards higher chemokine levels in HIV-Nef positive group versus the HIV 
negative control and the HIV-Nef-negative groups, which was especially remarkable for 
IP-10.  It would be interesting to address in longitudinal studies the relevance of these 
differences in the context of COPD development given that we have available PFT data 
(FEV1 and DLCO) and CT scans of the lung.  It would be desirable to test whether blood 
samples also reflect the changes observed in the lung (BAL). However, considering the 
dilution factor of BAL, all of the chemokines except for RANTES are found in much 
higher concentration in the lung when compared to the blood. Furthermore, the Nef 
effects are more pronounced in the lung versus the blood compartment, indicating that the 
observed changes in chemokines and possibly other cytokines are restricted to the lung. 
The cohort from which all the PBMC and plasma were analyzed do not have the 
exquisite characterization of the INHALD cohort. Future studies could look at plasma 
and PBMC from patients in the INHALD cohort to extend our findings. 
We discovered that HIV-Nef expressing T cells and PBMCs and HIV-Nef 
containing EV can induce HCAEC and ECFC stress. Combined with [42, 45] [50] 
previous observation of Nef containing EV in plasma of HIV patients on ART, our study 
highlights the possibility of HIV Nef containing, pro-apoptotic EV as inducers of 
endothelial dysfunction in HIV patients.  
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Specifically, this extracellular vesicle fraction from plasma and BAL was capable 
for inducing endothelial cell apoptosis. Although plasma in a 1:10 dilution with 
EGM2MV media only induced very low levels of HCAEC apoptosis, EV isolated from 
50μl of either plasma or BAL dissolved in 100μl of EGM2MV media from HIV+ patients 
potently induced HCAEC and HMVEC apoptosis respectively. The EV depleted plasma 
fraction was incapable of inducing endothelial cell apoptosis. Therefore, the Nef 
persistent fractions of PBMC and extracellular vesicles from both BAL and plasma are 
capable of inducing endothelial cell apoptosis. Furthermore, treatment with EMAPII 
neutralizing antibodies was capable of ameliorating both BAL fluid as well as BAL fluid 
EV induced HMVEC apoptosis. This offers a potential therapeutic option to counter 
EMAPII mediated Nef EV induced apoptosis. 
 
2 Inflammation and endothelial activation associated with Nef induced endothelial 
stress 
The ability of HIV-Nef to alter the chemokine profile of alveolar macrophages is 
important since Nef could act as a major mediatory of HIV associated inflammatory 
profile in the lung. These changes contributing to T-cell dysfunction are essential for 
regulation of immunity and inflammation, and thus can influence pulmonary disease 
development. They are also believed to be one of the major mechanisms leading to a 
consistent imbalance of the pulmonary microbiome [186-188]. This imbalance 
contributes to both chronic inflammation in the lung and acts as a potential source for 
increasing the risk of lung cancer. Using alveolar macrophages, we can further elucidate 
mechanisms behind our finding that Nef stratification is meaningful and leads to 
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significant differences when for example tested in endothelial apoptosis assays.  The 
ability of HIV-Nef containing EVs to promote an inflammatory phenotype can thus be 
studies in a lung-specific context. These findings reflect the ability of HIV-Nef 
containing EVs to promote activation of blood-derived monocytes and macrophages; a 
common feature in HIV associated end-organ diseases including neurocognitive disorders 
and atherosclerosis [43-47, 189]. On the other hand, the lung pathologies we 
characterized in our endothelial specific Nef-expressing mice can be attributed to 
increased endothelial cell apoptosis (Fig.39). Future studies expressing Nef from other 
cellular sources like T cells and macrophages or with the injection of Nef EV could study 
the contribution of endothelial activation and inflammation in Nef-mediated endothelial 
damage. Furthermore, these models can be used to characterize the effect of Nef EV on 
inflammation mediated endothelial damage.  
Pulmonary hypertension is another pulmonary vascular disease, in which HIV-
Nef has already been associated with [176, 190]. Here we show that BAL fluid derived 
EV contain HIV-Nef and that HIV-Nef containing EV induce EMAPII surface 
expression in primary human pulmonary artery endothelial cells (Fig.27). Furthermore, 
the addition of Nef EV to HPAEC and HMVEC also induced endothelial cell pro-
inflammatory phenotype as described by an increased surface expression of VCAM-1, 
ICAM-1, P-Selectin and E-Selectin (Fig.52 and 53) followed by increased T cell 
adhesion (Fig.55 and 56).  It is possible that HIV-Nef containing EV from lung act as the 
initial insult that results in the loss of endothelium that is characteristic of pulmonary 
arterial hypertension (PAH). We addressed the transfer of Nef to coronary vascular 
endothelial cells on several levels; increased interaction between HIV-Nef positive T 
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cells and HCAEC, HIV-Nef transfer through EV as a long-range transport mechanism, 
and finally we elucidated the mechanism of how HIV-Nef causes cytosol and its own 
transfer to HCAEC. 
Although nanotubes may in principle lead to transfer of HIV-Nef under static 
conditions [191, 192], in conditions of flow, extracellular vesicles maybe the preferred 
transport of cargo from latently infected HIV positive cells to the vasculature, as 
corroborated by a plethora of independent studies and investigators [40, 42, 43, 45, 48, 
193-196]. Our study shows that HIV-Nef expression increases communication of toxic 
EV cargo including the Nef protein between T cells and endothelial cells. The ability of 
statins to block this enhanced interaction could be crucial in preventing Nef transfer and 
subsequent endothelial dysfunction. 
The adhesion of lymphocytes to the vascular endothelium is a key driver in heart 
failure in both patients with non-ischemic heart failure and murine models of heart failure 
[197]. Specifically, the increased presence of endothelial adhesion proteins like ICAM1 
[198, 199] suggests a strong role in immune-mediated endothelial cell activation leading 
to endothelial dysfunction in HIV patients. Secreted factors from CD8+/CD28- T 
lymphocytes of HIV patients and HIV proteins like GP120 [200] and HIV-Tat [201, 202] 
were shown to promote lymphocyte adhesion to endothelial monolayer via upregulation 
of ICAM-1. HIV-Nef protein in the form of EV is capable of increasing endothelial cell 
adhesion markers like ICAM-1 in an ERK signaling dependent fashion [203]. HIV-Nef 
containing EV becomes the leading candidate to induce lymphocyte adhesion the 
endothelium since it fits both criteria of being a persistent circulating factor in HIV 
patients on ART and a secreted factor from T cells.  Again, statin treatment was capable 
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of abrogating Nef EV induced endothelial activation suggesting a potential mechanism 
for statin’s ability to reduce vascular dysfunction in HIV patients. 
In this model, we focused on the endothelium as the target tissue by expressing 
Nef through the endothelial cell specific promoter VE-Cadherin. , Given that Nef can 
lead to endothelial adhesion protein expression, the absence of inflammation in the lungs 
of these mice is surprising (Fig.40). It is possible that endothelial cell-only expression 
levels of Nef are insufficient to induce adhesion protein but EMAPII surface expression, 
which is expected to cause little inflammation but apoptosis. Surprisingly, our in vitro 
transmigration experiments showed no significant increase in transmigration of THP-1 
monocytes towards HMVEC treated with Nef-EV (data not shown) while alveolar 
macrophages treated with Nef-EV secrete pro-inflammatory cytokines (Fig.20). It is 
possible that Nef-EV induced adhesion protein induction acts over a longer period than 
can be effectively tested in migration assays. On the other hand, it could also be related to 
Nef’s inability to induce chemokines release from endothelial cells while a secondary cell 
type like macrophages might be needed to mediate this effect.  
In our murine models, HIV-Nef-induced induction of endothelial apoptosis rather 
than inflammation since we did not observe a significant rise in inflammatory immune 
cells in the BAL edema and only a slight trend towards protein content in the BAL 
(Fig.40). Hence, in this study, we focus on the contribution of endothelial cell apoptosis 
towards the development of pulmonary pathology. This observation is consistent with 
previous data showing that apoptosis of lung endothelial cells driven by VEGF receptor 
inhibitors is sufficient to cause emphysematous changes [204]. 
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While we do observe an increase in surface EMAPII expression in lung 
endothelial cells of Nef transgenic mice (Fig.28), we only detect a non-significant slight 
trend in the increase in secreted EMAPII in the BAL (Fig.40D). Previously, we have 
shown that EMAPII, which is secreted from the lung epithelium induces an emphysema-
like phenotype in mice with both increased apoptosis and inflammation in the lungs 
[142]. Future studies expressing HIV-Nef in other cell types including alveolar 
macrophages and injection of Nef containing extracellular vesicles can study whether 
HIV-Nef can also upregulate EMAPII secretion that in turn drives inflammation. These 
models are also required to evaluate the entire spectrum of immunological and 
pathological consequences of HIV-Nef-EV uptake by alveolar macrophages and other 
immune mediators. 
In a murine model of chronic ecoHIV, a chimeric HIV, in which the gp120 in 
HIV-1/NDK was replaced with that of gp80 from ecotropic murine leukemia virus 
(MLV) to establish chronic infection in immunocompetent mice developed COPD upon 
exposure to cigarette smoke [205].  ecoHIV infected mice had significantly reduced 
forced expiratory flow 50%/forced vital capacity and enhanced distal airspace 
enlargement following cigarette smoke exposure. HIV infection was detected in alveolar 
macrophages and contributed lung IL-6, granulocyte-macrophage colony-stimulating 
factor, neutrophil elastase, cathepsin G, and matrix metalloproteinase-9 expression. 
Similarly, IκBα, ERK1/2, p38, and STAT3 phosphorylation and lung cell apoptosis were 
also seen in this mouse model. It would be interesting to perform similar studies in our 
endothelial Nef expression model using a second hit of pulmonary stress like cigarette 
smoke exposure. EMAPII neutralizing therapy was shown to prevent the progression of 
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emphysema in a cigarette smoke exposure model of emphysema [142]. Therefore 
EMAPII neutralizing antibodies and statin treatment could be tested, along or in 
combination using this model of ecoHIV/cigarette smoke exposure to study whether they 
can protect from HIV and cigarette smoke exposure induced emphysema. 
3 Nef induced endothelial damage could prime the vasculature for disease 
Our finding that persistence of HIV-Nef protein in latent infection is relevant for 
an end organ disease reflects findings in other viral infection; such as adenoviral protein 
E1A persists in latent infections and primes the lung for the development of 
COPD/emphysema [206]. Similarly, the risk of developing pulmonary diseases like 
COPD is heightened in HIV patients on ART. Here we show that persistence of HIV-Nef 
protein in end organs like the lung could induce secretion of pro-apoptotic EV and thus 
act as a precursor for the development of pulmonary pathologies. In our exquisitely 
characterized ART-treated HIV patient cohort (Fig.1, 2 and Tables 1 and 3), we 
discovered a close correlation between HIV-Nef and EMAPII in BAL cells. This is in 
line with our previous demonstration that cigarette smoke also induces upregulation of 
EMAPII thus leading to endothelial apoptosis [142, 207]. Our findings showing that 
HIV-Nef can utilize an EMAPII mediated pathway to induce endothelial cell apoptosis is 
highly relevant to explaining lung pathologies in HIV patients since endothelial cell death 
has been suggested as an important mechanism for inducing lung emphysema in rodents 
[204, 208-210] and humans [211]. HIV-Nef induced cytotoxic lymphocyte activation and 
lung capillary endothelial cell apoptosis may explain the increased incidence of 
emphysema in HIV-infected patients [212]. Our results demonstrated that transgenic 
expression of HIV-Nef in the endothelium causes remodeling resembling 
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emphysematous changes (Fig.37 and 38) in the lungs of these mice. Given the recent 
proposition that endothelial cell apoptosis may be a common denominator for both 
emphysema and PAH development [213, 214], the mechanism here suggested about how 
HIV contributes to endothelial apoptosis should be of general interest. In this regard, our 
finding that Nef-induced EV release and biological activities to endothelial cells and 
alveolar macrophage is important. For example, targeting PAK2 activation dependent 
EMAPII pathways could be of therapeutic interest to combat HIV associated pulmonary 
vascular diseases. 
Cardiovascular dysfunction [215-218], impaired endothelium-mediated 
vasodilation [219, 220]  and arterial stiffening [221-223] are well established phenotypes 
in the HIV patient population. Similarly, endothelial dysfunction has been characterized 
in mammals including transgenic rats expressing HIV proteins [224], ex vivo porcine 
pulmonary arterial rings treated with HIV-Nef [225] and SHIV Nef infected macaques 
[226]. Our study sheds light on the ability of endothelial HIV-Nef protein to 
independently impair endothelium-mediated vasodilation and cause a mild vascular 
dysfunction phenotype even in the absence of other HIV associated confounding 
variables like ART, immune cell activation and viral replication.   
Transgenic expression of all HIV viral accessory proteins in mice [224], rats 
[227] and SHIV-infected macaque [228]  show a strong link between HIV and pulmonary 
vascular remodeling. Our observation of vascular remodeling in endothelium-specific 
HIV-Nef transgenic mice is the next piece of the puzzle in determining the source of 
vascular pathologies in HIV infected individuals on ART. Here we describe that HIV-Nef 
protein can potently induce endothelial cell apoptosis due to increased ROS production 
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by the NADPH Oxidase complex that is dependent on Rac 1 activation. This Nef-induced 
endothelial stress was ameliorated with statin treatment, both in vitro and in vivo showing 
the benefits of statin treatment even in the absence of dyslipidemia. 
4 HIV-Nef persistence as a common denominator for HIV associated vascular co-
morbidities 
Our study highlights how HIV infection could link pulmonary and systemic 
vascular diseases since Nef persistence is capable of affecting the endothelium regardless 
of location. In a study evaluating emphysema and coronary artery disease found an 
association between emphysema and coronary artery scores (Odds Ratio 1.43) after 
correcting for age, sex, smoking status, pack-years of smoking, visceral adiposity and 
duration of HIV infection[229]. This association was found be even higher (Odds Ratio 
1.52) when corrected for Framingham risk scores. This association could potentially be 
explained by using Nef persistence as a lens. Furthermore, comparison of Nef persistence 
in various compartments - blood, BAL and cerebrospinal fluid could be used to study the 
effect of HIV on end organ-specific vascular diseases.  
The endothelial progenitor cell population is also affected in HIV patients as these 
cells have impaired proliferative capacity and angiogenic potential in HIV patients [230, 
231]. Studies describing the frequency of circulating endothelial progenitor populations 
in HIV patients have conflicting reports depending on the classification of circulating 
endothelial cells [232] [233] [234] [231, 233, 235-237]. Here we show that HIV Nef-
expressing T cells and EV can induce senescence in these highly proliferative progenitors 
that have an important role in tissue repair. Since Nef protein persists in EV and is 
disseminated throughout the body, Nef EV’s capacity to induce ECFC senescence could 
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have longstanding implications on global circulations. HIV associated renal vascular 
disease [238] [239] and cerebrovascular [20, 240-244] disease are other end organ 
diseases prevalent in the HIV patient population. Therefore, future studies should explore 
Nef-induced damage to renal and cerebral vasculature to extend the findings from these 
studies. Furthermore, since ECFC were described to play an important role in not only 
vascular homeostasis but also for recovering from vascular injury. In this regard, the VE-
Cadherin Nef transgenic mouse model could be used in vascular injury models like hind 
limb ischemia, kidney ischemia-reperfusion, coronary artery ligation, and hypoxia 
exposure. Delayed or impaired repair response in these models and reduced capacity of 
ECFC to heal vascular damage could further explain the increased propensity of these 
diseases in the HIV patient population.   
5 Therapeutic strategies to counter Nef induced endothelial stress 
Our findings here suggest that HIV-Nef uses a Rac 1 mediated pathway to induce 
endothelial cell stress which in turn leads to endothelial dysfunction.  Downstream of 
Rac1 activation, we described that Pak2 kinase activation is important for mediating 
endothelial cell apoptosis since it leads to EMAPII surface expression that potently 
amplifies endothelial cell apoptosis. Targeting an HIV-induced pro-apoptotic pathway in 
endothelial cells via blocking EMAPII using neutralizing antibodies may be sufficient to 
treat HIV-associated pulmonary diseases. In support of this, short term treatment of mice 
with EMAPII neutralizing antibody was able to reduce the amount of apoptotic 
pulmonary endothelial cells. This suggests that long term treatment or treatment at the 
onset of Nef protein expression could reverse pulmonary vascular pathology 
development.  
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Furthermore, the Nef-Rac1-Pak2 signaling axis is important for both EMAPII 
mediated and ROS mediated endothelial cell stress. Treatment with SRC kinase 
inhibitors, PP2 and Nef-Hck signaling inhibitor, B9, did not block Nef-induced 
endothelial cell apoptosis (data not shown). EMAPII neutralizing antibodies and statin 
treatment provide promising workarounds to block downstream effects of Nef-induced 
Rac1-Pak2 activation. This is of special importance since Rac1 inhibitors could have side 
effects because of the important role of Rac1 in a wide variety of cell signaling pathways. 
On the other hand, Pak2 inhibitors like PF-03758309 have poor bioavailability (Clinical 
trial - NCT00932126). This makes targeting of Rac1-Pak2 signaling prophylactically in a 
global population of HIV patients a huge challenge. Hence, future ventures should be 
directed at unearthing specific inhibitors of Nef-Rac1 activation by targeting the PxxP 
motif – SH3 domain interaction site. Another strategy would be to test inhibitors that can 
block Nef-induced Pak2 activation by specifically blocking the 195 phenylalanine residue 
but does not interfere with Pak2 recruitment. Since only a small fraction of Pak2 is 
associated with Nef [89], inhibition of Nef-Pak2 activation should have minimal effects 
on essential Pak2 function but abrogate Nef-induced pathological Pak2 signaling. 
Our study provides the context for combination therapy to protect vascular health 
in HIV patients. Upon diagnosis with HIV+, in addition to starting patients on 
antiretroviral therapy, an initial α-EMAPII neutralizing antibody treatment could help 
slow down EMAPII's apoptosis driven feed-forward loop that promotes endothelial 
stress. 
Statins have been deployed in clinical trials like REPRIEVE to study their ability 
to prevent cardiovascular diseases in HIV patients [245]. Rosuvastatin, Atorvastatin, and 
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Pitavastatin have been shown to protect HIV patients from the development of CVD to a 
larger extent than can be attributed to a drop in LDL [246-252]. Specifically, Atorvastatin 
and Pitavastatin have minimal to no drug-drug interactions with ART, making it 
attractive to prescribe to HIV patients. [253-256]. Subsequently, similar to the 
REPRIEVE trial, HIV patients can be placed on statin therapy to target Nef-induced Rac1 
activation which should reduce Nef EV release as well as ROS production and 
endothelial apoptosis that follows the uptake of Nef EV. Pitavastatin’s ability to reverse 
HIV-Nef induced effects on ECFC is in line with other studies showing the benefits of 
statin treatment on endothelial progenitor population in murine models [257-260] and 
clinical trials of statin intervention [261-265]. 
6 Conclusion 
HIV-Nef protein persists in HIV patients on ART at levels comparable to those 
not on therapy. Furthermore, Nef protein was identified in extracellular vesicles of 
bronchoalveolar lavage fluid as well CD4, CD8 T cells and Alveolar Macrophages 
isolated from bronchoalveolar lavage. These findings highlight the importance of 
studying Nef protein persistence and its effect on endothelial dysfunction in HIV patients. 
The ability of statin treatment to block HIV-Nef mediated Rac 1 signaling could help 
limit vascular dysfunction in HIV patients on ART and potentially delay the development 
of cardiopulmonary vascular diseases.  
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